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ABSTRACT 
 
 The purpose of the present study was to examine the effects of eight weeks of resistance 
training and pre-workout supplementation on lean body mass, strength, and markers of 
inflammation.  Twenty four (n=24) healthy, recreationally active, college aged males (19.5 ± 1.3 
years) volunteered for this study.  Individuals were randomly assigned to supplement (SUP) or 
placebo (PCBO) groups and drank either a multi-ingredient supplement or color and taste 
matched placebo 15 minutes prior to exercise three times per week for 8 weeks.  Strength and 
body composition testing was performed before and after the training period.  Muscle biopsies 
and blood draws were performed immediately before and after the first and last exercise bouts.  
Skeletal muscle and serum samples were analyzed for markers of inflammation. Repeated 
measures ANOVAs revealed significant differences in lean body mass across subjects following 
training [F(1, 22) = 20.320, p < 0.01].  Significant differences in squat, bench press, leg 
extension, leg curl and lat pulldown 1-repetition maximum (RM) strength following training 
were also found, (p < 0.01).    No significant differences in lean body mass [F(1, 22) = 0.994, p > 
0.01] or strength were seen between SUP and PCBO groups (p > 0.01).  Pairwise comparisons 
revealed significant decreases in skeletal muscle IL-6 when comparing pre to post training time 
points [PRE 1-POST1, t(23) = 4.661, p < 0.01; PRE2-POST2, t(23) = 4.875, p < 0.01].  No 
significant changes IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IFN-γ, or TNF-α were observed 
(p > 0.01).  No significant differences in cytokine levels were found between SUP and PCBO 
groups (p > 0.01).  Further research examining the cytokine response to resistance exercise and 
the effects of supplementation on the inflammatory response is warranted. 
KEY WORDS: IL-6, TNF-α, cytokines, resistance training 
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CHAPTER I 
INTRODUCTION 
 Cytokines are proteins manufactured and secreted by many cells of the body that play 
crucial roles in the proliferation, growth, and maturation of cells (112).  Skeletal muscle is 
crucial to the production of several cytokines including interleukin (IL)-6, IL-8, IL-15, and 
possibly IL-4 (112).  The cytokines that are produced within skeletal muscle are now more 
commonly called myokines.  The production of IL-6 has been of particular focus to date as 
changes in plasma values of this protein are associated with both body composition and physical 
activity levels (40-41).  In general, individuals who are obese and inactive have higher levels of 
IL-6 (41).  Over production of IL-6, combined with a high level of tumor necrosis factor-alpha 
(TNF-α) has been proposed to lead to type II diabetes mellitus (113).  Recent evidence has 
revealed that high basal levels of IL-6 are generally due to the hyperproduction of this cytokine 
by the adipose tissue (87).  However, contraction of the skeletal muscle is also associated with an 
increase in IL-6.  This conflicting evidence has led many to question the role for the skeletal 
muscle production of IL-6. 
 The increase in IL-6 in the skeletal muscle with acute exercise is associated with an 
increase in IL-6 receptor, and is also responsible for the dramatic increase in plasma IL-6 with 
exercise (74).  Plasma levels of IL-6 have been shown to increase up to ten-fold immediately 
following one hour of aerobic exercise and gradually decrease to baseline during one hour of 
recovery.  Research has shown that IL-6 plays a central role in metabolism; regulating both 
glucose uptake as well as lipolysis (4, 50, 114).  Due to this positive role, IL-6 has been deemed 
an anti-inflammatory cytokine (121).  TNF-α however, due to its role in protein degradation is 
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considered a pro-inflammatory cytokine.  These two cytokines generally act in opposition to one 
another with the exception of individuals with insulin resistance and type II diabetes mellitus as 
previously mentioned (70-71, 104).   
Both IL-6 and TNF-α are associated with a downstream signaling cascade of mediators 
that play a role in the regulation of metabolism.  Specifically, IL-6 release is associated with an 
increase in IL-10, whose role is to inhibit the pro-inflammatory marker IL-1β which is linked to 
TNF-α release (135).  Other cytokines downstream of IL-6 include IL-8 and IL-4 which 
respectively promote angiogenesis and skeletal muscle satellite cell proliferation (45, 67).  IL-6, 
IL-10, and interferon (INF)-γ have been implicated as anti-inflammatory proteins, however 
studies have shown conflicting results on the role of IFN- γ in skeletal muscle degradation (110, 
126, 146).  While these cytokines act in response to the release of IL-6, IL-15 is not directly 
associated. IL-15 has been shown to increase with skeletal muscle contraction; however, it has 
not been shown to play a role within the skeletal muscle itself (21).  Increases in IL-15 have been 
associated with reduced white adipose tissue (98, 117).  Few studies have examined changes in 
IL-15 and acute and chronic exercise using a human model (120).   
Due to the influence of cytokines on metabolism, the impact of carbohydrate ingestion 
prior to and during prolonged exercise has been examined.  In general, these studies have 
revealed glucose ingestion during exercise attenuates the IL-6 and downstream response to 
exercise (39, 100).  The implication of carbohydrate ingestion on IL-15 is unknown.  Many other 
ingredients are commonly included in pre-workout supplements.  These include, but are not 
limited to caffeine, creatine, and amino acids.  The literature examining the in vivo inflammatory 
response to these additives are limited; however, the response to caffeine, some amino acids, and 
Vitamin E have been explored in cell culture and rodent models (47, 61, 64-65, 68, 148). 
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Analysis of the role of caffeine on fitness measures are varied; some revealing this supplement 
will improve strength, while others find no influence on strength or muscular endurance (11-12, 
51, 149-150).  Despite this, studies have suggested caffeine is associated with a decrease in 
circulating TNF-α (47, 65). Similarly, intake of the amino acid glutamine has been linked to an 
increase in strength following training, as well as a decrease in TNF-α in culture and mouse 
models (148). Some have revealed increases in strength and power with L-arginine and α-
ketoglutarate supplementation; however, none have examined inflammation with their intake 
(22).  Β-alanine supplementation is associated with reduced fatigue and improved muscular 
endurance, but again no research has determined its influence on inflammation (61-62).  Creatine 
supplementation has been widely studied revealing increases in strength, muscular endurance, 
and lean body mass; however, it too has not been examined from an inflammatory perspective 
(13, 85, 90, 142).   
While studies have examined the skeletal muscle production of myokines during acute 
and chronic aerobic exercise as well as acute anaerobic exercise, few studies have examined the 
influence of regular resistance training on the inflammatory response.  With pre-workout 
supplementation becoming increasingly popular, further research on the metabolic role of these 
products and their influence on resistance training adaptations and the immune response are 
necessary.  
I. Statement of the Problem 
 Skeletal muscle IL-6 mRNA and thus plasma IL-6 and downstream cytokines as well as 
IL-15 have been shown to increase in response to acute aerobic and anaerobic exercise, 
respectively (99, 134).  TNF-α and IL1-β however generally do not change with exercise (70). 
Chronic exercise training has been associated with an increase in IL-6 receptor and thus lower 
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circulating levels of basal IL-6 (50).  To date few studies have examined the inflammatory 
response to a total body resistance training exercise bout, or a long-term resistance training 
program.  In addition, no studies have examined the influence of a pre-workout supplement 
containing caffeine, creatine, various amino acids, among other ingredients on the inflammatory 
response to an acute bout of exercise. 
Therefore, the following hypotheses were tested in college aged recreationally trained, healthy 
males: 
1.  An acute bout of total-body resistance training will result in an increase in serum IL-
6, IL-10, IL-4 as well as an increase in IL-15 within skeletal muscle.  TNF-α and IL-
1β levels will remain unchanged.  
The pre-workout supplementation will not significantly alter anti or pro-
inflammatory cytokines produced during an acute bout of total body resistance 
training.   
2.  An 8-week total body resistance training program will result in a decrease in basal 
serum IL-6, TNF- α and IL-1β, and an increase in skeletal muscle IL-15. 
The pre-workout supplementation will not result in any significant differences in 
cytokine production.  
3.  An acute bout of total-body resistance training following an 8-week total body 
resistance training program will result in an increase in serum IL-6, IL-10, and IL-4.  
This increase will be significantly lower than before training.  The same bout of acute 
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exercise will be associated with a significantly greater IL-15 production within 
skeletal muscle. 
The pre-workout supplementation will not significantly alter anti or pro-
inflammatory cytokines produced during an acute about of total body resistance 
training following an 8-week resistance training program. 
4.  The 8-week resistance training program will be associated with an increase in 
strength and lean body mass.   
The pre-workout supplementation will not significantly affect changes in strength 
or lean body mass. 
II. Rational for the Investigation 
Recent research has established the role of anti and pro-inflammatory cytokines on 
metabolism (112).  Most research however, has focused on the effect of acute aerobic exercise 
and chronic aerobic training on inflammatory adaptation.  Evaluating the effect of resistance 
training on the skeletal muscle IL-15 protein and body composition changes will allow for a 
further understanding of the role of this cytokine.  Understanding the skeletal muscle and serum 
IL-6 and TNF-α response to this exercise could provide insight to proper training programs for 
individuals suffering from metabolic disorders including type II diabetes mellitus.  Finally, 
supplementation of caffeine and amino acids that have previously shown to decrease the pro-
inflammatory cytokine TNF-α will provide insight to possible effects of this supplement on 
metabolism in recreational weight lifters and its possible pharmacological use in diseased 
populations.    
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CHAPTER II 
REVIEW OF LITERATURE 
 
The Role of Cytokines in Skeletal Muscle 
Research has shown that physically active individuals have lower plasma basal IL-6 than 
sedentary individuals (40-41, 113).  The increase in exercise induced IL-6 mRNA has been 
shown to decrease with aerobic training, while the IL-6 levels in plasma are generally similar 
before and after training (42).  Examination of rat soleus and extensor digitorum longus (EDL) 
muscles following eight weeks of aerobic training revealed significant decreases in IL-1β, IL-6, 
TNF-α, and IL-10 in the EDL (84).  Another study demonstrated IL-6 receptor mRNA increases 
during an acute bout of exercise as well as following ten weeks of training (72).  It is the changes 
in IL-6 receptor that can be associated with any changes in IL-6 due to training (72). 
 While IL-6 rises in response to acute exercise, the subsequent rise in IL-6 receptor in 
skeletal muscle tissue during an acute exercise bout has been linked to glucose regulation (50).  
Research has shown the rise in IL-6 is also associated with increased glucose uptake due to 
increases in intrinsic glucose transporter, GLUT4 (4, 114).  Exercise following training has 
shown reduced gene expression of IL-6 and IL-6 receptor as well as reduced IL-6 plasma 
concentration (3). In addition, it has been shown that glucose ingestion during exercise and 
exercise training reduces the change in IL-6 receptor by blunting the IL-6 response, thus 
reducing the overall increase in IL-6 receptor following aerobic training (3). 
  IL-6 release is also associated with an increase in free fatty acids within the blood and 
an increase in lipolysis (4, 140).  Current research suggested skeletal muscle contraction induces 
an anti-inflammatory effect by the release of IL-6 and its downstream signaling, while at the 
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same time the adipose tissue has a pro-inflammatory response (122).  These differences could be 
due to increased lipolysis necessary for energy production during exercise (122).   Similarly, a 
previous study demonstrated rats with an IL-6 deficiency develop obesity at greater rates than 
wild-type rats (145).  In addition, IL-6 infusion over 18 days resulted in decreased body weight 
in the IL-6 deficient rats (145).   This further identifies the role of IL-6 in the increase in fatty 
acids during exercise.  The link between IL-6 and substrate metabolism could be adenosine 
monophosphate-activated protein kinase (AMPK) (4).  IL-6 has been shown to increase AMPK 
in skeletal muscle, which is associated with increases in fatty acid oxidation and glucose uptake 
(4).   
Despite these positive changes elicited by IL-6, the inflammatory marker is also 
associated with the activation of the protein, suppressor of cytokine signaling (SOCS) (113).  
SOCS3 increases in the skeletal muscle and even more so in the liver (110).  This protein is 
commonly associated with insulin resistance.  These differences in the role of IL-6 have led to 
confusion concerning the benefit of this marker in the anti-inflammatory response.  It has been 
suggested there is an upper limit to the positive effects of IL-6.  Hyperproduction of IL-6 is 
related to not only insulin resistance and type 2 diabetes, but a myriad of problems related to 
metabolism including obesity and atherosclerosis.  The overproduction of this cytokine occurs 
along with receptor dysfunction of the glucocorticoid receptor.  IL-6 production from adipose 
tissue also accounts for this overproduction of IL-6, as adipose is the main source of increased 
IL-6 at rest (87, 97). Release of IL-6 from adipose tissue is not associated with the increase in IL-
6 with exercise.  Similarly, hyperproduction of IL-6 does not allow for the typical exercise effect 
on IL-6.  In addition, it has been shown that insulin resistance in skeletal muscle may be directly 
related to fat cell size (125). The Akt/PKB pathway is directly related to glucose uptake into 
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skeletal muscle.  Skurk et al. (85) revealed that secreted markers from isolated fat cells reduce 
insulin stimulated Akt/PKB phosphorylation contributing to obesity-linked insulin resistance.  
These changes were seen across several markers secreted from the tested adipocytes including 
but not limited to IL-6 and IL-8.  The difference in the basal levels of IL-6, and the changes with 
IL-6 in response to exercise could be the keys to distinguishing between detrimental and normal 
changes in IL-6 production.  
IL-6 has also been implicated in the regulation of tumor necrosis factor (TNF)-α.  While 
many have suggested the combination of the two play a role in a variety of diseases, more recent 
evidence has shown that TNF-α is the pro-inflammatory marker (71). When TNF-α is present 
there is decreased GLUT4 translocation which is related to decreased skeletal muscle glucose 
storage (111).  TNF-α and IL-1β have been implicated in the cause of muscle damage and 
wasting in many diseases (123).  One of the most significant health-related benefits of increases 
in IL-6 during exercise and the subsequent increase in IL-6 receptor following training is its role 
on TNF-α.  Research suggests IL-6 release during exercise suppresses TNF-α release (113).  One 
previous study found an acute bout of exercise lowers TNF-α in individuals with high basal 
levels of TNF-α (71).  In fact, IL-6 infusion has been shown to upregulate IL-1ra and TNF 
receptors.  While the decrease in TNF- α is partly contributed to an increase in IL-6, it has been 
noted that this decrease still occurs in IL-6 deficient mice suggesting another mechanism yet to 
be determined plays a role in this change (128).   
 The differences in the influence of TNF-α and IL-6 have further supported the conclusion 
that anti-inflammatory and pro-inflammatory classes of cytokines exist.  Many have studied the 
complex signaling pathways that contribute to the activation of these markers, but much about 
this process is still not understood. Further examination of the cytokine response to resistance 
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training exercise is necessary to more fully understand the role of cytokines within the skeletal 
muscle. 
 
Cytokine Signaling within Skeletal Muscle 
 Research within the last decade has revealed the major role of the skeletal muscle in the 
production and release of cytokines (134).  The origin of several cytokines were originally 
thought to be related to endotoxin stimulated monocytes and macrophages in association with the 
general inflammatory response to infection (35).  It was suggested that the eventual activation of 
NFκB (nuclear factor of κB) was responsible for the transcription of genes related to cytokines 
IL-6, TNF-α and IL-1β (82).  In this pathway lipopolysaccharide (LPS), a bacterial endotoxin 
found in the cell wall of Gram-negative bacteria, would bind to Toll-like receptor (TLR)-4 and 
cause MyD88 (myeloid differentiation primary-response protein 88) to move to its cytoplasmic 
domain (81).  This then caused IRAK-1 (IL-1 receptor associated kinase-1) and TRAF-6 (TNF-α 
receptor associated factor-6) to activate IkappaB kinase (IKK)-NFκB pathway and this led to the 
production of IL-6 and other cytokines (82).  However, it is now evident that many types of cells 
outside of the immune system can also produce IL-6.  Skeletal muscle in particular has been 
shown to produce IL-6 in response to reactive oxygen species (ROS), inflammatory cytokines 
(TNF-α and IL-1β), and during contraction in human and animal models (86).  Due to its 
production within the skeletal muscle, IL-6 is commonly called a myokine (112).   
IL-6 production by the skeletal muscle was revealed in 2000 (134). It was suggested this 
increase is the source of the increase in plasma IL-6 during exercise (134).  More recently it has 
been shown that the increase in IL-6 during exercise is purely due to the skeletal muscle (115).  
This was revealed when no change was seen in the number, percentage, and mean of IL-6 
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positive stained monocytes following prolonged cycling (129).  A later study by the same 
laboratory revealed that the number of monocytes staining positive for IL-6 actually decreased 
following prolonged running (130).   
In addition, the IL-6 mRNA in skeletal muscle has been shown to increase up to 100-fold 
at the end of a prolonged exercise bout (133).  The nuclear transcription of IL-6 increases 
significantly at the start of exercise (73) allowing for an increase in IL-6 at approximately 30 
minutes of exercise, and generally peaks when exercise is stopped (133).  While increases in IL-
6 produced by the skeletal muscle are significant, it is also important to note that limiting IL-6 
release using 4 weeks of Vitamin C and E supplementation blocked the IL-6 release from 
muscle, but only decreased plasma IL-6 by 50% (42).  This further proves skeletal muscle 
significantly contributes to circulating IL-6 but also draws attention to the fact that other cells are 
responsible for IL-6 production.  Although adipose tissue has been associated with releasing IL-6 
at rest, it has been shown that these tissues do not release IL-6 during exercise (87). Further 
research examining the IL-6 production of other cell types during exercise is necessary to fully 
understand the inflammatory signaling cascade 
Several cytokine signaling theories currently exist. The cell signaling that occurs in 
response to LPS, ROS, and inflammatory cytokines has also been linked to the mitogen-activated 
protein kinases (MAPKs).  During skeletal muscle contraction the role of this pathway could be 
of particular interest during states of muscular glycogen depletion.  It has been previously shown 
that p38 MAPK is related to physiological stressors including skeletal muscle contraction.  
Contraction induced increases in stress kinases including c-jun amino-terminal kinase (JNK) 1 
and 2 and p38 MAPK increase as the energy supply is low in a glycogen depleted state.  It is 
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speculated that p38 activation may lead to activation of a particular transcription factor that binds 
to the regulatory region of the IL-6 gene during skeletal muscle contraction (27).   
 There are conflicting opinions regarding the influence of the NFκB pathway on IL-6 
production during skeletal muscle contraction.  Studies have revealed when nonsteroid anti-
inflammatory drugs, substances known to inhibit the NFκB pathway, are administered during 
exercise, IL-6 is reduced suggesting this pathway plays an important role in the IL-6 production 
(78).  Others have demonstrated that IκB which plays a role in the IKK-NFκB pathway does not 
increase the transcription of IL-6, suggesting this pathway does not play a role during 
contraction.  Still others have revealed the NFκB pathway is associated with inhibition of 
differentiation related to muscle wasting and muscle damage conditions, suggesting this protein 
is more likely to have a pro-inflammatory effect (80). 
 Muscle glycogen levels also play a role in IL-6 production.  Several studies have revealed 
IL-6 production in skeletal muscle is greater in tissues that have low glycogen levels (26, 101).  
When individuals ingest supplemental glucose during exercise the IL-6 release is inhibited, 
however IL-6 mRNA expression within the working muscle is not affected (39).  Research has 
revealed that IL-6 within the plasma decreases as the IL-6 receptor production decreases, 
suggesting there is a mechanism of sensitivity of the muscle to the exercise induced effects of IL-
6 when IL-6 levels are low (26).  It is also suggested that the IL-6 receptor could be involved 
with energy restoration within the muscle (26).  The role of epinephrine in IL-6 production has 
also been examined.  As fuel in the form of carbohydrates is reduced during exercise, there is an 
increase in the sympathetic response causing an increase in epinephrine.  Researchers questioned 
if this response could be related to the IL-6 response, however recent evidence does not support 
this theory (111).  Still others have suggested that AMPK may be related to IL-6 production 
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within the skeletal muscle tissue (88).  AMPK activity is also associated with low levels of 
muscle glycogen, and has been shown to be correlated with higher IL-6 production; however, no 
direct link between these two proteins has been proven.   
 Calcium activation of nuclear factor of activated T-cell (NFAT) has also been a 
suggested mechanism associated with IL-6 production during skeletal muscle contraction.  It is 
commonly known that skeletal muscular contraction is associated with the sarcoplasmic 
reticulum release of calcium.  NFAT is generally activated during sustained calcium release.  
However, studies have yet to demonstrate a significant increase in NFAT during exercise.  It has 
been suggested however that the quick dephosphorylation by calcineurin and rephosphorylation 
by NFAT kinases and movement to the nucleus does not allow for significant changes in the 
abundance of this protein at a specific point during or immediately following exercise, making it 
difficult to examine its relationship with IL-6 production.  However, research has shown the 
calcineurin pathway is upregulated through ionomycin treatment and resulted in an increase in 
IL-6 in a time and dose dependent manner (103).  Cyclosporin A (30), an inhibitor of calcineurin 
pathway, is associated with an increase in TNF-α.  These differences revealed that IL-6 and 
TNF-α are independently regulated (70), suggesting IL-6 release is directly related to the 
calcineurin pathway while TNF-α is related to the inactivity of this pathway. 
Calcium has further been referred to as a potential regulator of IL-6 production through 
studies of the inflammatory response to exercise in different skeletal muscle fiber types.  In 
general, these studies have revealed that type II fibers produce more IL-6 than type I fibers over 
the same time period (59, 122).   Hiscock et al. (59) suggested this might be due to signaling of 
an unknown IL-6 transcription factor as a result of greater calcium influx in the type II 
contracting tissues.  However, if duration is considered, prolonged exercise that relies heavily on 
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type I skeletal muscle will produce a low amplitude of Ca
2+
 influx which is known to activate 
calcineurin (9).  Research has shown that inhibition of calcineurin using cyclosporin A and 
FK506 reduced IL-6 activity and thus proved the role of calcineurin on the production of IL-6 
(9).  These researchers also suggested calcineurin plays a significant role in the transcription of 
the IL-6 in types I and IIa fibers, as these levels increased as markers of calcineurin activity 
increased (10). 
  Still another possible mechanism of IL-6 production within the skeletal muscle exists.  
Recent studies have suggested that nitric oxide (NO) may also be associated with the regulation 
of gene transcription in skeletal muscle (132).  Nitric oxide is significantly increased in 
contracting skeletal muscle.  Research has shown that inhibiting NO during exercise reduces IL-
6 mRNA production and increase of IL-6 protein release from skeletal muscle. Furthermore, the 
infusion of NO is associated with increased IL-6 in resting skeletal muscle (132). 
 It is also possible that a combination of these mechanisms is responsible for the increase 
in IL-6 with exercise.  It has been shown that in  B lymphocytes, the amplitude and duration of 
calcium release directly controls activation of NF-κB, c-Jun amino-terminal kinase (JNK), and 
NFAT (38).  NF- κB and JNK are generally activated by large increases in calcium, while NFAT 
is regulated by longer, sustained calcium release.  However, based on research examining IL-6 
release in response to various exercise types, Febbraio and Pedersen (38) suggested the IL-6 
release is more likely Ca
2+
/NFAT regulated.  In a review of IL-6 signalling pathways, Febbraio 
suggested the potential roles for each of the mechanisms discussed above (37).  He suggested 
that an increase in Ca
2+
 during exercise activates IL-6 gene transcription.  As exercise duration 
increases, the calcineurin-NFAT pathway is associated with increases in IL-6.  In addition 
Febbraio suggests that increased exercise intensity, marked by a significant increase in Ca
2+ 
flux, 
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activates NF-κB and JNK.  Prolonged exercise that results in low glycogen availability is then 
associated with the activation of p38 MAPK and possibly the activation of NF-κB (37).  No 
matter what the specific cause of the increase in IL-6 may be, research has shown that this 
cytokine is associated with the regulation of other inflammatory markers. 
The Influence of IL-6 on Downstream Cytokine Signaling 
It has been suggested that IL-6 is associated with the regulation of several cytokines 
including TNF-α, IL-1, and IL-10.  TNF-α is associated with NF-κB stimulation (80).  
Specifically, the TNF-α receptor 1 ‗death domain‘ interacts with TNF receptor-associated death 
domain (TRADD), activating fas-associated death domain and kinase receptor interacting protein 
(110).  These proteins are involved with the regulation of apoptosis through the TNF-α related 
activation of NF-κB.   NF-κB is located in the cell cytoplasm bound to the inhibitory protein 
IκBα, however TNF-α upregulation results in the phosphorylation of IκBα.  This allows for the 
release of IκBα, possibly due to the increase in mitochondrial reactive oxygen species related 
caused by TNF-α and eventual activation of the ubiquitin proteosome pathway (123).   
Many studies have reported that TNF-α does not change during or immediately following 
prolonged exercise, with the exception of prolonged high intensity exercise such as marathon 
racing (70, 104, 127).  In fact, several reports concerning the relationship between IL-6 and 
TNF-α now agree that IL-6 actually inhibits TNF-α and IL-1 release, while allowing for the 
release of IL-1ra and IL-10.  However, others have shown that TNF-α has been suppressed in IL-
6 knock-out mice, suggesting that while IL-6 may play a role in this process, there is another 
mechanism that limits TNF-α production at the start of exercise (71).  Still others have focused 
on skeletal muscle fiber type and differences in cytokine expression.  Rosa Neto et al. (122) 
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recently found TNF-α mRNA expression increased following exhaustive exercise in the extensor 
digitorum longus (EDL) but not soleus muscles in rats. 
The absence of IL-6, TNF-α and IL-1β have been implicated in the repression of 
hormones related to skeletal muscle growth, specifically growth hormone and insulin-like growth 
factor-1 (75, 135).  These changes are associated with a reduced protein expression throughout 
the body, including the reduced expression of differentiation factors specific to muscle.  The 
activation of TNF-α receptor 1 (TNF-R1) and IL-1 receptor 1 (IL-1R1) are associated with the 
activation of the JNK pathway which causes resistance to IGF-1, among other hormones (135).  
Recently it has been shown that the presence of IL-1 in skeletal muscle myotubes is associated 
with an activation of p-38 MAPK and NF-κB signaling (80).  In this specific study, the exposure 
to IL-1 over 48 hours resulted in a reduction in the width of the myotubes as well as a reduction 
in actin within the sarcomere.  Kelley et al. (75) suggested this is likely due to IL-1β inhibition of 
typical IGF-1 signaling.  Strle et al.(135), however; revealed IL-10 inhibits the function of IL-1β 
thus allowing for normal IGF-1 signaling.  Since it has been previously shown IL-6 release from 
skeletal muscle during contraction is associated with an increase in serum IL-10 (131), it is 
possible than IL-6 actually contributes to the normal IGF-1 response.  
Still other studies have suggested TNF-α may have a positive role on skeletal muscle 
growth.  Plaisance et al. (116) demonstrated incubation of C2C12 myotubes with TNF-α for 24 
hours increased protein synthesis.  This increase was demonstrated by an increase in ERK1/2 and 
downstream targets as well as an increase in Akt and downstream targets GSK-3, p70s6k, and 
4E-BP1.  This upregulation was decreased when an inhibitor of TNF-α was administered.  
Similarly, when rapamycin was used, while mTOR was inhibited, there was no effect on the 
upregulation of P13K-Akt or MED-ERK activation due to the increased TNF-α.  These findings 
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reveal more research is needed examining the influence of these cytokines on skeletal muscle 
function.  This is contrary to previous work by de Alvaro et al.(34) which suggested the 
phosphorylation of p-38 resulted in the impaired activation of the PI3K-Akt signaling and thus 
glucose uptake, leading to insulin resistance. 
Previous research has demonstrated that an increase in IL-10 via LPS is associated with 
an inhibition of IL-1α, IL-1β, IL-6, IL-8, and TNF-α gene transcription (35) suggesting IL-6 and 
IL-8 are targeted by IL-10 as well.  Within the skeletal muscle however evidence has suggested 
this is not the case.  Recently IL-6, IL-8, and IL-10 are considered anti-inflammatory cytokines, 
providing further evidence that the increase in cytokines following exercise is not the same as the 
cytokine response that is initiated by an infection (121).  IL-10 has been associated with 
inhibiting the expression of proinflammatory cytokines as well as their receptors.  Recent 
evidence has revealed IL-10 may specifically act to block the IL-1β phosphorylation of JNK, but 
not other pathways in MAPK signaling (135).  This suggests IL-10 may play a role in preventing 
IGF-1 resistance and thus insulin resistance.  However, again recent evidence suggests the 
response of this cytokine also might be a fiber type specific response, as IL-10 has been shown to 
increase in EDL rat muscle following extensive exercise without changes in soleus tissue (122).   
Early studies of the effect of exercise on the inflammatory response demonstrated an 
increase in plasma IL-1  up to five days post eccentric aerobic exercise suggesting that this 
cytokine my play a role in the catabolic or anabolic process within the muscle (23).   However, 
the release of IL-6 has been shown to be associated with inhibition of IL-1 (121). As previously 
discussed, IL-1β is a pro-inflammatory protein that often leads to protein degradation.  However, 
IL-1ra blocks the binding of IL-1α and IL-1β to IL-1 receptors and effectively inhibits the effects 
of IL-1. IL-6 is considered the major inducer of IL-1ra.  It is possible that earlier studies 
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exhibiting an increase in IL-1 for several days post exercise did not distinguish between IL-1ra 
and IL-1β (46).  
 IFN-γ is another cytokine associated with the adaptive immune response and commonly 
associated with the immune response to exercise.  The role of IFN-γ, and whether this cytokine is 
involved in the inflammatory or anti-inflammatory process, is debated.  Many have noted this 
cytokine is often increased with TNF-α in mouse and culture tissues (110, 146).  The presence of 
TNF-α and INF-γ in myotubules have resulted in a decrease in myosin mRNA expression (1).  
Many assumed this suggested IFN-γ is an inflammatory cytokine (110, 126, 146).  However, 
recent evidence suggests these two cytokines do not act in the same manner (28, 126).  It has 
been reported that treatment with INF- γ did not affect reactive oxygen species activity, which 
has been demonstrated to be a common occurrence with an increase in TNF-α (126).  In addition, 
72 hours of IFN-γ did not result in any change in the MHC content.   This evidence suggests 
IFN-γ and TNF-α may not play a similar role in the inflammatory response (126). In addition, 
this demonstrates that IFN-γ may not have a catabolic role.   
 An early study examining the inflammatory response to prolonged running revealed no 
change in IFN-γ post exercise (137).  However, Cheng et al. (28) recently reported IFN-γ is 
expressed in both mRNA and protein levels in myoblasts within damaged muscle.  This suggests 
the muscle itself may produce this cytokine following injury.  This study also revealed blocking 
IFN-γ receptor in mice was associated with reduced myotubule proliferation as well as reduced 
fiber regeneration (28).  In addition, following a more severe injury of the muscle such as a 
laceration, IFN-γ has been shown to improve the healing of the muscle while reducing fibrosis, 
or scar tissue formation (44).  These findings suggest IFN-γ may be necessary for muscle 
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growth. It has also been suggested the immune role of this cytokine includes macrophage 
activation, antiviral and antitumor activity, as well as the production of free radicals (17).   
The production of free radicals may reveal a role for IFN-γ following exercise or muscle 
damage. IFN-γ signalling is directly related to the JAK-STAT signaling from the IFN-γ receptor 
complex (109).  More specifically, ligand binding of this complex activates Jak1 and Jak2 and 
the dissociation of STAT1 from this complex.  STAT1 then translocates to the nucleus and binds 
to the gamma activating site (GAS) inducing transcription of IFN-γ promoters.  One such 
promoter is IRF-1 which is responsible for identifying the interferon stimulation response 
element (ISRE) which also is associated with the expression of IFN-γ and subsequent free radical 
production (110). 
As discussed, it has been demonstrated that IL-6 produced within the skeletal muscle in 
response to contraction produces a downstream signaling of cytokines related to the 
inflammatory state.  The production and release of these markers are associated with the 
signaling crucial to tissue repair.  The differences in the release of these IL-6 are often related to 
the duration, intensity, and type of the exercise stimulus.  
Influence of Exercise Duration, Intensity, and Mode on Cytokine Signaling 
 The influence of exercise on the cytokine response has largely focused on the role of IL-
6, as this myokine is the first activated and elicits the most pronounced increase during exercise.  
In addition, IL-6 is associated with the increase of several other cytokines as well as an inhibition 
of pro-inflammatory markers.  Serum levels of IL-6 have been shown to significantly increase 
during prolonged aerobic exercise in active and inactive individuals (18-19, 49, 73-74, 87, 105-
106, 108, 133-134, 139).  These changes were shown to be greater in a nonactive population 
(49).  An examination of five minutes of intense aerobic exercise  showed a slight, but not 
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significant increase in IL-6, suggesting the duration of exercise might be key to changes in IL-6 
(18).  Studies of prolonged aerobic exercise have all shown an increase in IL-6 however the 
duration of that increase varies.  Many studies have revealed IL-6 peaks at the end of exercise 
(105, 133). One study revealed IL-6 returned to baseline after one hour of recovery from 60 
minutes of cycling at 70% of VO2max (139).  Still others have reported IL-6 has a more gradual 
decrease over time, with IL-6 declining over a four hour recovery period following two or more 
hours of exercise (106, 108, 127).  Another study even reported a peak in IL-6 at three hours post 
exercise (18).  In general, only exercise lasting more than one hour has been shown to result in 
10-fold increases in IL-6 (112).  Some have suggested that the intensity as opposed to the 
duration of the exercise might be the key in explaining these differences (108).     
 Changes in IL-6 during and following anaerobic exercise have been debated.  IL-6 has 
been shown to increase immediately during anaerobic sprint intervals (95).  Another study 
showed that circuit weight training (5 exercises performed at 3 sets of 10 repetitions) resulted in 
an increase in IL-6; however, this was not significant (19).  A recent study found no significant 
changes in plasma IL-6 following resistance exercise bouts of 50%, 75%, 90%, and 110% of 
one-repetition maximum for the bench press exercise (138).  Some have suggested the increase 
in IL-6 following exercise is independent of muscle damage (18, 127); although this is debated 
(19). 
 Others have examined changes that occur with cytokines and regular training.  Main (91) 
examined significant changes in serum IL-10, TNF-α, and IL-12 over the course of a 12 week 
training period in elite rowers.  These cytokines, as well as IL-6 gradually increased over time 
peaking just before a taper began. IL-1β levels, while not significant, were at their lowest at this 
point.  Significant changes were also noted between cytokines as exercise duration and intensity 
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changed. Specifically, a significant interaction was observed between training distance and 
training duration for all measured cytokines except for IL-6 and IL-1β.  Only one study to date 
has examined the influence of regular resistance training on the serum cytokine response.  This 
study revealed an acute bout of exercise following resistance training results in an increase in IL-
6, IL-1ra, and IL-10 as well as the pro-inflammatory IL-1β (69).  These findings however are in 
contrast to previous analysis of aerobic training. Fischer et al. (42) found skeletal muscle mRNA 
for IL-6 is actually decreased following aerobic training, and plasma IL-6 is generally the same 
before and after training.  Keller et al. (72) revealed an acute bout of exercise following training 
results in an increase of IL-6 receptor mRNA suggested any changes in IL-6 as a result of 
training are actually due to changes in the IL-6 receptor.   
Some have suggested that the type of exercise performed effects the inflammatory 
response to exercise.  For instance some studies have suggested that exercises that focus on areas 
of smaller muscle mass may result in a significant increase in IL-6 (58, 102, 138).  It has been 
suggested that running causes the greatest inflammatory response (112).  Other studies have 
suggested eccentric exercise which is commonly associated with muscle damage, does not cause 
significantly greater IL-6 response than concentric exercise but may affect the recovery process 
(89, 147).  These studies revealed plasma IL-6 may peak up to six hours following eccentric 
exercise and may take up to 96 hours or more to return to baseline levels; both of which are 
longer time periods than are typical for other types of exercise.  To date, no studies have 
examined the local inflammatory response to a resistance training program.  However previous 
information suggests type, duration, and intensity of exercise all play a significant role in the IL-
6 response.   
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Additional Myokines: IL-8, IL-15, IL-4 
IL-8 
While much of the literature has focused on IL-6, two other anti-inflammatory markers, 
IL-8 and IL-15, are also considered myokines as evidence has shown they are also produced 
within the skeletal muscle (112).  As previously discussed, NO production is associated with IL-
6 production.  Evidence has also shown that NO is also associated with the transcription of IL-8 
in skeletal muscle (132).  Akerstrom et al. (2) revealed increases in IL-8 mRNA following three 
hours of cycling and the same response after three hours of knee extensor exercise at 60% of 
maximum.  Similarly, Frydelund-Larsen et al. (45) showed IL-8 receptor protein was elevated 
levels at 3, 4.5, 6, 9, and 24 hours following three hours of cycling.  Despite changes within the 
skeletal muscle, neither study found significant changes in plasma IL-8 suggesting this myokine 
has an immediate localized effect (2, 45).  However, post marathon plasma IL-8 has been shown 
to peak 0.5 hours after exercise (107).  Frydelund-Larsen et al. (45) also examined CD105, the 
TNF-β receptor which is expressed in endothelial cells in response to hypoxia (exercise), and IL-
8 receptor protein.  Their study revealed CD105 was coexpressed with IL-8 receptor protein 
levels.  This finding suggests IL-8 is primarily located within the microvascular endothelial cells 
and may play a role in angiogenesis within the skeletal muscle. 
IL-15 
Previous evidence has indicated that IL-15 is the most prevalent cytokine in skeletal 
muscle, and has the highest IL-15 content of the body (120).  In contrast to the role of IL-8, IL-
15 is associated with decreased protein degradation within the skeletal muscle.  Specifically, IL-
15 has been shown to decrease the activity of the ubiquitin/proteasome pathway (21).  Busquets 
et al. (21) further state IL-15 does not play a role in an increase in protein synthesis.  In fact, IL-
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15 may play a role in the inhibition of TNF-α releated apoptosis.  However, increases in IL-15 
mRNA have been expressed in skeletal muscle following an acute bout of resistance exercise in 
untrained individuals (97).  This increase took place without increases in skeletal muscle or 
plasma IL-15 protein. Quinn et al. (119)  had also previously demonstrated that IL-15 stimulated 
a five-fold increase in myosin heavy chain (MHC) expression in already differentiated myocytes.  
This increase in MHC occurred in the absence of IGF-1 suggesting that this change must occur 
through another mechanism.  These findings reveal IL-15 could play a role in the skeletal muscle 
preservation during periods of disease when IGF-1 levels are low including cancer or sepsis  
(118).  Another study revealed an increase in plasma IL-15 protein immediately following acute 
resistance training exercises, as well as following chronic training (120). This study examined 
the influence of 10 weeks of resistance training involving 3 sets of 6-10 repeptitions of 13 
exercises.  Skeletal muscle hypertrophy following training has been linked to changes within 
specific untranslated regions within the IL-15ra gene, suggesting the presence of this myokine 
effects phenotype (120).   
More recently, several studies have suggested IL-15 may play a significant role in the 
regulation of body composition (5, 24, 100, 117).  Carbo et al. (24) revealed that seven days of 
IL-15 administration to rats resulted in no change in muscle mass but a 33% reduction in white 
adipose tissue and decreased lipoprotein lipase. Alvarez et al. (5)  revealed similar findings in a 
later study of leptin receptor negative and leptin deficient rats.   Later analysis of transgenic mice 
that overexpressed IL-15 demonstrated no change within the skeletal muscle, but revealed 
significant decreases in body fat and increases in bone mineral density without changes in any 
other cytokines (117).  Nielsen et al. (98) examined the relationship between IL-15 mRNA 
expression, plasma IL-15 and obesity levels in a cohort of 199 individuals to reveal a negative 
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relationship between fat mass and circulating IL-15.  Within the same study, the overexpression 
of IL-15 in mice revealed a decreased body fat accumulation in the trunk with no change in 
subcutaneous fat.  Further research is needed examining the changes in IL-15 and body 
composition following exercise programs in human models. 
IL-4 
Although IL-4 is not yet deemed a myokine, recent evidence suggests it may also be 
produced within the skeletal muscle.  Few studies reporting the inflammatory response to 
exercise have examined IL-4.  However, Horsley et al. (67) reported IL-4 played a role in 
myogenesis when using a transgenic mouse model.  More recently, Lafreniere et al. (79) 
revealed in human cells IL-4 plays a role in the second step of myogenesis during which 
myoblasts fuse with myofibers, and thus suggesting IL-4 contributes to hypertrophy of the 
skeletal muscle.  In addition, these researchers demonstrated IL-4 also attracts other cell types, as 
well as myogenic precursor cells to the site of muscle injury; thus, decreasing the myoblast 
migration rate.  The upregulation of IL-4 in skeletal muscle is associated with the 
calcineurin/NFAT pathway (66, 152).  Specifically, the activation of NFATc2 is associated with 
myotubular growth and results in the activation of IL-4 transcription (66).   
The study of IL-8, IL-15, and IL-4 as myokines has been a relatively recent development 
when compared to the study of IL-6.  Little is known about the influence of exercise mode, 
frequency, intensity, and duration on these proteins.  Similarly, examination of pathways 
responsible for the increase in these proteins is warranted. 
   
 
 
24 
 
Pre-Workout Nutritional Supplementation and the Cytokine Response 
 Nutritional supplements are often consumed before or during both aerobic and anaerobic 
events to improve performance.  These supplements can range from energy sources including 
various forms of carbohydrates and proteins, to vitamins, minerals, amino acids and many other 
varieties.  Few studies have examined the use of these substances prior to exercise and their 
influence on the inflammatory response. 
Carbohydrates 
 Carbohydrates are commonly ingested prior to as well as during long-term aerobic 
exercise as a means to prevent skeletal muscle glycogen depletion and thus reduce amino acid 
oxidation (54, 144, 151).  Van Loon et al. (141) suggested that carbohydrate supplementation 
every thirty minutes during prolonged cycling actually resulted in an increase in glycogen 
synthesis.  In addition, glucose supplementation has been shown to improve attention as well as 
mood and reduce overall fatigue during prolonged physical activity (83). 
 Ingestion of carbohydrates before or during a resistance training workout has been 
associated with an increase in post-exercise insulin and growth hormone levels which can be 
linked to an increase in protein synthesis (29).  In addition, Haff et al. (52) concluded that 
carbohydrate ingestion (0.3g/kg body weight) prior to a resistance training bout improved 
performance of multiple squat sets performed four hours post training.  Haff et al. (53) later 
revealed carbohydrate consumption prior to isokinetic leg exercise significantly improves 
performance as noted by increases in total and average work.  Additionally, plasma glucose was 
significantly higher in the supplementation group while no changes in free fatty acids or lactic 
acid were revealed. 
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 As previously mentioned, carbohydrate ingestion prior to exercise has been shown to 
significantly influence the inflammatory state.  More specifically, consumption of a 6% 
carbohydrate drink before and every 15 minutes during 2.5 hours of exercise results in a 
significantly different inflammatory response than consumption of a placebo (101).  This study 
revealed higher plasma glucose and insulin accompanied by lower levels of IL-6 and IL-1ra 
cytokines with carbohydrate supplementation.  Similarly, Stanley Chan et al.(25) revealed 
individuals in a glycogen deprived state produced higher levels of IL-6 and IL-8 mRNA during 
and following 60 minutes of cycling.  No significant changes were found in IL-1β, IL-15, and 
TNF-α.  Febbraio et al. (38) had previously revealed similar findings and also showed IL-6 
release was attenuated in subjects who ingested a 6.4% carbohydrate solution at 15 minute 
intervals throughout the exercise.  Despite this, there was no increase in skeletal muscle IL-6 
mRNA expression.  Fewer studies have analyzed the cytokine response to carbohydrate 
supplementation and resistance training.  Koch et al. (77) found carbohydrate intake resulted in 
increased post exercise plasma glucose without significant differences in the lymphocyte 
response to resistance training; however, intramuscular or plasma cytokines were not examined. 
Caffeine 
 Caffeine is also a common ingredient in pre-workout supplements.  This common 
ingredient is a form of methylxanthines which are known antagonists to adenosine receptors 
(32).  While many supplements list caffeine as an ingredient, others list methylxanthines.  Past 
research on the effects of caffeine consumption on performance has produced conflicting results.  
Early studies of caffeine supplementation revealed caffeine ingestion prior to aerobic exercise 
significantly improved performance (15, 31).  Bergland et al. revealed caffeine consumption of 
6mg/kg body weight resulted in an improved 21km cross country race times at both low and high 
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altitudes (15).  Similarly, Costill et al. (31) noted that 330mg of caffeine consumption one hour 
prior to cycling resulted in a longer time to exhaustion.  In addition, caffeine intake was 
associated with increased lipolysis and lower ratings of perceived exersion.   
Later studies of the effects of caffeine have focused on its influence on strength and 
power.  Woolf et al. (149) demonstrated an increase in peak power during Wingate ergometer 
testing as well as an increase in bench press 1-RM in well-trained athletes following ingestion of 
a shake containing 5mg/kg body weight of caffeine and 0.125g/kg body weight of carbohydrates.  
Green et al. (51) found ingestion of 6mg/kg body weight of caffeine 1 hour prior to exercise 
reduced fatigue in well-trained subjects.  These subjects were asked to complete 3 sets of leg 
press to fatigue at a weight equal to their 10-RM.  Those who had ingested the caffeine were able 
to complete more repetitions during their final set of the exercise than those who had consumed a 
placebo.   
 Despite these studies suggesting caffeine aids in performance enhancement, many studies 
have revealed conflicting data.  For example, Woolf et al. (150) found no difference in 40 yard 
dash, 20 yard shuttle, or 1-RM bench press performance in collegiate football players following 
5mg/kg body weight of caffeine.  Similarly, Beck et al. (12) found no change in leg press 1-RM 
or endurance or bench press endurance following a supplement containing yerba mate, guarana, 
and black tea extract, all of which contain caffeine.  However, this study did reveal and increase 
in bench press 1-RM.  In other studies, caffeine did not significantly change 1-RM bench press, 
running time to exhaustion, VO2peak or body composition (11 7, 92).  While many factors may 
have played a role in these differing results, Fisher et al. (43) suggested the subjects‘ tolerance to 
caffeine may explain why the findings from these studies have varied.  This study revealed that 
individuals who habitually had caffeine in their diet (788±75mg/day) acquired a tolerance to the 
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substance.  These individuals did not see any significant changes in aerobic performance 
following the consumption of 5mg/kg body weight of caffeine. 
 While these previous studies examined the role of caffeine in aerobic and anaerobic 
measures, fewer studies have looked at the influence of caffeine on markers of inflammation.  
One study examined the influence of caffeine and paraxanthine, a byproduct of caffeine within 
the body, on cytokine and TNF-α response (65).  A cell culture model demonstrated that when 
these substances are added in an amount typical of human consumption to blood mononuclear 
cells, TNF-α was significantly reduced.  In addition, no changes in IL-10 or IL-1β were found.  
Dray et al. (36) revealed three different doses of caffeine, all typical of human consumption, 
resulted in a decrease in TNF-α gene expression in human adipocytes in culture.  Similarly, 
Geraets et al. (47) found a decrease in TNF-α gene expression at 4 hours and 24 hours post 
treatment of 1,7 dimethylxanthine, a byproduct of paraxanthine.  This study also showed a 
decrease in TNF-α in patients suffering from chronic obstructive pulmonary disorder.  It was 
suggested these changes were associated with a disruption of the NFκB pathway.  Finally, in 
healthy subjects, 1,7 dimethylxanthine consumption was associated with a decrease in IL-6.  To 
date, no studies have examined the influence of caffeine and exercise on markers of 
inflammation.   
Creatine 
 The use of creatine supplementation has been extensively studied (13, 56, 85, 90, 143).  
These studies have examined the role of creatine in skeletal muscle hypertrophy, strength and 
endurance.  No studies to date have examined creatine supplementation and inflammation. Many 
creatine studies employ both a loading and a maintenance supplementation phase.  In general, 
this consists of 20g of creatine monophosphate/day for a period of 5 days followed by 5-10g of 
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creatine/day for several weeks of training.  These phases of supplementation have been 
associated with increases in strength and body mass (13, 143).  Creatine supplementation has 
also been associated with increased muscular endurance as measured by bench press fatigue (56, 
85).  However, other studies have shown increases in strength with lower creatine doses (20, 56, 
64, 85).  In addition, Herda et al. (56) compared 30 days of 5g of creatine supplementation with 
low (1.25g/day) and high (2.50g/day) polyethylene glycosylated (PEG) creatine to find strength 
increased in all groups.  Despite this, no change in body mass, power, or endurance were 
observed in those consuming PEG creatine.   
Changes in strength associated with creatine supplementation are associated with 
increases the intracellular stores of total creatine which contributes to an increase in anaerobic 
capacity and muscle mass when supplementing a resistance training program (109).  This 
increase has been linked to skeletal muscle hypertrophy due to an increase in growth hormone 
delivery, contractile protein synthesis, and reduced protein catabolism (109).   Despite positive 
changes in overall body mass, lean body mass, muscular strength and endurance following 
creatine supplementation, these studies have not shown changes in body fat percentage.  Others 
have suggested if the supplementation dose not adequately increase the skeletal muscle creatine 
stores, these changes will not occur.  While many studies examining creatine supplementation 
have revealed positive performance adaptations, still others have revealed differing results, and it 
has been suggested inadequate creatine concentration within the muscle has been the differing 
factor.  Other studies have also suggested the use of small samples of elite athletes and resistance 
training programs not designed to increase strength may also explain the differences found in 
these studies.  
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Amino Acids 
 Pre-workout supplements commonly include a combination of the above ingredients as 
well as other nutrients including amino acids.  The amino acids of interest in the current study 
include arginine, glutamine, tyrosine, and alanine.  L-Arginine has been suggested to be involved 
in protein synthesis including creatine synthesis, and the removal of ammonia.  Supplementation 
of high doses of L-arginine (30g intravenous infusion) has been shown to be a physiological 
precursor of nitric oxide (NO), a mediator of vasodilation (16).  Smaller doses of L-arginine 
(3g/day) have been linked to a decrease in exercise induced plasma lactate and an increase in L-
citrulline (124).  These authors suggested the inverse relationship between L-citrulline and 
lactate support the theory that L-arginine increases the nitric oxide pathway during exercise.  
Another study examined the influence of L-arginine and α-ketoglutarate on strength and power 
changes following an 8 week supplementation and resistance training program (22).  This study 
revealed supplementation of 6g of L-arginine and 6g of  α-ketoglutarate per day for 8 weeks 
resulted in an increase in strength as measured by 1-RM bench press as well as an increase in 
power as determined by Wingate testing.  Despite these positive changes, no changes in body 
composition (total mass, fat mass, lean body mass, or body fat) or aerobic capacity were 
observed in this study.  To date, no studies have examined the influence of L-arginine on 
inflammation. 
 Glutamine is commonly included in pre-workout supplements as depletion of this amino 
acid has been associated with an increase in muscle catabolism (6).  Thus, supplementing 
glutamine is an attempt to reduce the catabolism during the exercise bout.  Recent evidence has 
shown that glutamine supplementation of 0.9g/kg of LBM per day during a six week resistance 
training program result in significant increases in strength or LBM when compared to changes 
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within a placebo group.  However, glutamine has been closely linked to leukocyte function and 
may play a central role in immune function.  Specifically, several studies have examined the role 
of this amino acid on cytokines.  In a cell culture sepsis model, glutamine was associated with 
decreased TNF-α in circulation and an increase in heat shock protein 72.  A similar study 
revealed high levels of glutamine was associated with decreased TNF-α at both 4 and 24 hours 
following the addition of the amino acid to culture (148).  Meador et al. (94) examined glutamine 
supplementation and force production using a mouse model.  In this study, plantar flexor 
isometric force production was measured two hours after LPS injection.  This resulted in a 33% 
decrease in maximal force production and an increase in TNF-α and IL-6.  However, when 
glutamine was supplemented at 1g/kg BW, there was no significant change in pre to post force 
measures.  TNF-α levels were the same while IL-6 levels were lower than the non-supplemented 
trial suggesting glutamine plays a role in maintaining force production during acute 
inflammation.  In contrast, Hiscock et al. (60) suggested 3.5g glutamine ingestion at 60 minutes 
and 105 minutes into a cycling bout did not significantly change IL-6 production.  It is possible 
that these differences in IL-6 release following supplementation could be due to the type of 
exercise employed, the model used, or the supplement dose.  Further study is necessary to 
determine the role of glutamine on the inflammatory response to exercise. 
 As previously stated, alanine and taurine are other amino acids commonly included in 
pre-exercise supplements.  Alanine has been associated with an increase in intramuscular 
carnosine, which is associated with pH buffering as well as the regulation of calcium sensitivity 
and electron coupling (55).  This study revealed both lower doses (3.2g/d) and moderate doses 
(6.4g/day) of β-alanine for four weeks resulted in significant increases in carnosine.  Similarly, 
Hill et al. (57) revealed an increase in carnosine following 10 weeks of β-alanine 
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supplementation in cyclists.  Hoffman et al. (61) examined 4.8g/day of β-alanine 
supplementation on an acute bout of resistance exercise (6 sets of 12 repetitions of the squat at 
70% 1-RM).  Following supplementation subjects were able to perform approximately 22% 
more repetitions of the squat exercise, suggesting β-alanine aided in improvements in muscular 
endurance.  Similarly, an study of three weeks of β-alanine supplementation in college football 
athletes resulted in an increase in bench press training volume and lower subjective feelings of 
fatigue among athletes (62).  Despite these changes, no differences were seen in fatigue ratings 
following high intensity exercise.  However, Kendrick et al. (76) examined 10 weeks of 
resistance training and β-alanine supplementation (6.4g/day) and found no significant differences 
in muscular endurance, strength or body composition.  When comparing the effects of β-alanine 
and taurine supplementation and a downhill running muscle damage protocol in rats, Dawson et 
al. (33) revealed taurine was associated with an increase in circulating glutamate, a decrease in 
lactate dehydrogenase, and improved running performance.  β-alanine was also associated with a 
decrease in lactate dehydrogenase but also a significant decrease in body weight following 24 
hours of exercise.  The authors concluded that this data suggested taurine has a cytoprotective 
effect to attenuate muscle injury.  To date, no research has provided information concerning the 
role of these amino acids on inflammation. 
Additional Ingredients 
 Other common pre-workout supplement ingredients of interest are betaine, citrulline, 
Vitamin E and tyrosine.  Few studies have examined the role of betaine on performance, 
however Hoffman et al. (63) revealed 1.25g ingested twice a day for 15 days resulted in an 
improved lower body muscular endurance as noted during a fatiguing squat protocol.  No 
differences were seen in bench press endurance or bench press throw, vertical jump, or Wingate 
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power tests.  Similarly, Maresh et al. (93) did not find any significant differences in lower or 
upper body endurance, isometric bench or squat measures, vertical jump or bench press power 
following 15 days of betaine supplementation. 
 Citrulline malate has been associated with an increase in oxidative energy production in 
individuals with fatigue (14).  This increase in aerobic function following 15 days of 
supplementation could have been associated with an increased malate supply and therefore 
increase in ATP production from the tricarboxylic acid cycle.  Giannesini et al. (48) also found a 
decrease in pathological fatigue in rats supplementing 1g creatine malate/kg of body weight three 
times per day over a 48 hour time period following LPS injection.  In a human model, Sureda et 
al. (136) found that supplemental L-citrulline prior to a cycling stage race increase plasma 
arginine availability and thus increased NO synthesis in peripheral blood mononuclear cells.  
This study suggests that citrulline may be a beneficial supplement for aerobic exercise, yet few 
studies have focused on its role in resistance training. 
 Few studies have examined the supplemental roles of Vitamin E and tyrosine.  One study 
did reveal 100mg/kg of body weight of tyrosine ingestion decreased symptoms, improved mood, 
and reduced performance impairments in individuals placed under cold and hypoxia stress for 
4.5 hours (8).  While no studies have examined the roles of betaine, citrulline, or tyrosine and the 
inflammatory response, Vitamin E has been shown to have a beneficial role.  Specifically, 48 
days of ingestion of 800IU/day was associated with a reduction in IL-1β release following a 
downhill running bout (97).  Despite this there were no differences in TNF-α release between 
supplement and placebo groups.  Another study examined three days of Vitamin E 
supplementation in skeletal and cardiac tissue in culture and determined this exposure decreased 
IL-6 and IL-1β response to LPS and prevented NFκB activation in these tissues (68).  Further 
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research is necessary to determine the role of many ingredients included in common supplements 
on inflammation. 
Conclusion 
In summary, the current understanding of the inflammatory response includes a role for 
skeletal muscle in the production and release of many cytokines including IL-6, IL-8, IL-15 and 
possibly IL-4.  The release of IL-6 has been shown to result in downstream effects on other 
markers of inflammation including IL-10, TNF-α and IL-1β.  These cytokines play important 
roles in metabolism regulation.  Because myokines are produced within the skeletal muscle, 
exercise has been shown to influence the presence of these markers.  While most research has 
examined the roles of duration, frequency, intensity and mode of exercise on the inflammatory 
state, few studies have examined the influence of a total body resistance bout, or chronic 
resistance training on plasma or tissue levels of the aforementioned cytokines.  Furthermore, the 
influence of pre-workout supplements on the inflammatory state remains to be determined.  
Caffeine and glutamine supplementation have previously been associated with decreases in TNF-
α.  The influence of Vitamin E on TNF- α has also been examined, however no role has been 
determined.  To date, no studies have examined the roles of other common supplement 
ingredients including creatine, tyrosine, or the amino acids arginine, alanine, or taurine.  
Similarly, the influence of a combination of these ingredients on adaptations to acute or chronic 
resistance training has not previously been examined. 
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CHAPTER III 
METHODS and PROCEDURES 
 
Experimental Design    
Thirty college aged, recreationally trained subjects were randomly assigned to either 
supplement (SUP) or placebo (PCBO) groups.  The study was double blind in nature as only the 
researcher preparing the supplement and placebo drinks was aware of the individuals who were 
assigned to either group.  The nine week study consisted of a two pre-testing sessions during 
week one, followed by eight weeks of training and testing.  A timeline of the testing and training 
procedures can be seen in Figure 1.  All subjects completed pre-testing strength and body 
composition testing the week prior to the training program start.  Subjects were asked to 
complete a log of their food and drink consumption for three days prior to the first training day.  
During the first day of the training program subjects reported to the Applied Physiology 
Laboratory (APL) following a four hour fast.  Blood samples and muscle tissue samples were 
obtained before exercise.  Subjects then consumed either the SUP or PCBO drink provided to 
them and waited fifteen minutes to begin their workout.  Fifteen minutes following the workout 
an additional blood draw and muscle biopsy were performed.   
Following the first training day subjects reported to the APL three days per week for their 
training sessions.  Prior to each workout subjects consumed their assigned drink (SUP or PCBO) 
and rested fifteen minutes until beginning their workout.  Workouts completed were primarily 
designed to increase skeletal muscle hypertrophy by using a combination of core and accessory 
lifts.  
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Testing of the 1-RM was again completed at the beginning of week five.  This data 
allowed for the proper progression of the subjects‘ training sessions.  Strength and body 
composition post testing were again completed during the final week of the study.  Prior to the 
final day of training subjects again were asked to complete a three-day food and drink log and 
report to the APL following an overnight fast.  Muscle biopsies and blood draws were again 
obtained before and fifteen minutes after the SUP/PCBO drink and workout session.  The 
workout performed was the same workout that was performed during the first day of training 
however the loads were changed based on the subjects‘ new 1-RM values.   
Subjects 
Thirty, non-smoking, recreationally active college aged males (n=30) volunteered to 
participate in this investigation.  All subjects gave written informed consent to the study protocol 
which was in accordance with the Declaration of Helsinki and approved by the Human Subjects 
Committee, Lawrence KS requirements (see Appendix A).  Subjects health history, exposure to 
materials used in the biopsy protocol, physical activity level, and caffeine intake were screened 
via questionnaires prior to their admission to the study (see Appendices B, C, D, E).  Individuals 
were selected as participants if they met the following inclusionary criteria: between 18 and 35 
years of age; exercised 3 days per week for at least 1 year; non-obese; non-smoker; no history of 
cardiovascular or metabolic disease risk; no history of computed tomography (CT), PET, or 
nuclear medicine studies within the last year; no history of allergies to local anesthetics, 
adhesives, or ingredients in the placebo or supplement; no history of adverse reactions to 
caffeine; and no use of anti-inflammatory medications or medications that may adversely react 
with the placebo or supplement.     
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Testing Protocol  
All subjects completed two pre-testing sessions prior to the beginning of the training 
program.  The first day involved 1-RM testing of the squat, bench press, leg extension, leg curl, 
and lat pulldown exercises.  Subjects performed warm-ups of 8-10 repetitions at 70% of their 
predicted 1-RM and 3-5 repetitions at 85% of their predicted 1-RM.  Subjects were given 2 
minute rest periods between warm-up sets and 3-4 minutes rest between maximal effort attempts.  
On the second day of pre-testing, body composition measurements were taken.  Individuals‘ 
weight was measured using an electronic scale, height was measured using a stadiometer, and 
body composition was determined using a Lunar Prodigy Dual X-Ray Absorptiometry (DXA) 
Scan (General Electric, Waukesha, WI). 
During the first week of the training program, subjects completed additional 1-RM 
testing.  This testing took place on the second training day of the week and involved testing 
exercises that would only be performed during the second training day of each week for the 
remainder of the program.  The exercises tested on this day included the dead lift, incline press, 
and bicep curl.  The warm-up and 1-RM protocol followed the same guidelines previously 
described. 
Mid-point testing was completed five weeks into the training program, 1-RM for the 
squat, bench press, leg extension, and leg curl were again measured.  These measurements were 
taken during the first training day that week.  Following their 1-RM testing, subjects then 
completed the remainder of their workout.  Subjects‘ weight was again measured at this point.   
Post-testing occurred during weeks seven and eight of training.  During week seven of 
the program 1-RM testing was completed for the dead lift, incline bench, and bicep curl 
exercises on the second training day.  Immediately following testing subjects completed the 
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remainder of their workout for the day.  During week eight of the training program, subjects 
repeated the pre-testing procedures during days 1 and 2 of their training week.  Again, during the 
first day 1-RM was determined for squat, bench press, leg extension, leg curl and lat pulldown.  
During the second day weight and height were again measured and post-training body 
composition was determined using the DXA scan. 
Training Protocol.   
The goal of the exercise training program was to increase muscular hypertrophy and 
strength.  The exercises performed varied with each day, however each day included both core 
and accessory lifts.  Day one and day three of each week were similar and included back squats, 
bench press, leg extension, leg curl, lat pulldowns, a back or shoulder exercise and weighted 
abdominal exercises.  Day two of the training program included dead lift, incline bench press, 
split legged squats, bicep curls, pull-ups, dips, and abdominal exercises.  The detailed list of the 
exercises included in the program is presented in Table 3-1.   
The exercises that were considered core exercises, or those of the main focus of the 
program, were the squat, bench press, leg extension, leg curl, lat pulldown, deadlift, incline 
press, and bicep curls.  The weight lifted for these exercises was based on the individuals‘ 1-RM.  
The weight for weeks 1-4 were based on the pre-testing 1-RM.  Following the mid-point testing 
at week 5, the weight was adjusted according to changes in the new 1-RM.  Finally, the last 
workout session was adjusted according to the post-testing 1-RM.  The percentage of the 1-RM 
lifted for these exercises varied week to week to progressively overload the musculature and 
allow adaptation.  A breakdown of the weekly training volume can be found in Table 3-2 and 
Table 3-3.   
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The accessory exercises included standing overhead press, pull-ups, dips, split legged 
squat, high pull, and abdominal exercises.  However, following mid-point testing many subjects 
were having difficulty lifting a load associated with their new 1-RM for the lat pulldown 
exercises, so these were moved to the accessory category with the exception of the final workout.  
For their accessory lifts, subjects were instructed to lift a weight that would fatigue them in 12 to 
15 repetitions.  That is, the subject could not possibly lift the weight more than 15 times.  For the 
pull-up and dip exercises subjects were allowed to use an assisted machine if needed, while 
others were instructed to add weight when their body weight became too easy.  Subjects were 
instructed to take approximately 90 seconds to two minutes rest between all sets of both core and 
accessory exercises. 
All exercise sessions were monitored by individuals working in the APL.  Initially, 
subjects were trained on a one-on-one basis.  However, after approximately a week and a half 
when the subjects were comfortable with the workouts subjects were allowed to work out in 
small groups yet still monitored by APL staff.  Close attention was paid to the sets, repetitions, 
rest, and weight being lifted to ensure that subjects were completing the workouts properly. 
Supplementation 
Subjects were randomly assigned to SUP and PCBO groups.  The supplement contained 
64 calories, all from carbohydrates, as well as, but not limited to the following ingredients:  
nitrous malate, taurine, arginine alpha-ketoglutarate, L-citrulline, L-tyrosine, caffeine, creatine, 
betaine, picamilon, beta-alanine, N-acetyl-L-glutamine, L-histidine, vitamin A and Vitamin E.  
The nutrition label for this supplement can be seen in Appendix F.  The placebo contained a low-
glycemic flavor and color matched drink sweetened with polydextrin and/or mannitol.  
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Each drink was prepared by measuring two scoops (32 grams) of the assigned powder 
into a water bottle.  Upon each subject‘s arrival to the lab for training approximately twelve 
ounces of water was added to the mixture, the bottle was shaken and given to the subject.  The 
subject consumed the drink and waited fifteen minutes before beginning their training session.  
Following the initial training and biopsy session the dose of the placebo and supplement was 
reduced to half for one and a half weeks.  This was done in an attempt to help the subject become 
accustomed to drinking it prior to their workout.  After this, all subjects consumed the full 
dosage of the drink.  During each visit to the lab all subjects completed a Supplement Side-Effect 
Questionnaire (See Appendix G) to examine if individuals were experiencing any problems such 
as nausea or light-headedness immediately following the use of the drink or any other problems 
later in the day or the days between sessions.  Blood pressure was monitored once each week and 
recorded on this questionnaire.  These Side-Effect Questionnaires were filed and reviewed by the 
study‘s Data Safety Monitoring Board.   
Blood and Muscle Sample Collection 
All muscle tissue samples were taken from the vastus lateralis using a needle biopsy 
technique by either Dr. Philip Gallagher or Dr. Andy Fry.  Subjects were asked to lie on an 
examination table so that the muscles of the legs were relaxed.  The skin was thoroughly cleaned 
with Betadine prior to the procedures.  Approximately 2ml of 2% Lidocaine was injected into the 
tissue under the skin around the site sampled. Following the injection of the numbing agent, a 
minimum of five minutes passed to ensure adequate time for the agent to take effect. During this 
time approximately 10ml of blood was drawn from the antecubital vein in the arm.  Once the 
numbing agent had taken effect on the leg a small incision (1 cm) was then made in the skin 
overlying the muscle, the biopsy needle inserted into the muscle belly at a depth of 
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approximately 3 cm, and a sample was obtained.  Following the biopsy procedure, firm and 
constant pressure was placed on the wound to stop any bleeding. The incision site was closed 
with a Steri-Strip or butterfly Band-Aid, covered with a large Band-Aid, and the site was 
compressed using a pressure wrap.  Muscle samples were sectioned, flash frozen and stored in 
liquid nitrogen until later analysis.  Blood samples were centrifuged at 3000g‘s for 20 minutes 
and stored in the -80° freezer for later use.   
Blood and Muscle Sample Analysis 
All muscle samples were analyzed for IL-6 and IL-15 protein.  Approximately 20mg of 
each muscle sample was homogenized in extraction buffer using a glass on glass tissue grinder.  
Homogenized samples were centrifuged at 4°C at 3,000g‘s for 4 minutes.  Supernatant was 
separated from the pellet and the sample was diluted (1:1000), and total protein concentration 
determined using a bicinchoninic acid (BCA) protein assay (Pierce; Rockford, IL). 
 Muscle samples were then diluted with 5x buffer and heated for 3 minutes.  Samples 
were loaded at a protein concentration of 80µl and ran on a 5% stacking and 10% separating gel 
at 0.03mA for 1 hour.  Proteins were transferred to hydrophobic polyvinylidene difluoride 
(PVDF) membranes at 0.02mA for 2 hours.  Membranes were blocked for 1 h in a Tris-buffered 
saline with 5% nonfat dry milk on a rocker at room temperature. Membranes were then 
incubated on a rocker overnight in a 1:1000 IL-6 and IL-15 antibody/TBST and 1% nonfat dry 
milk solution.  Following the overnight incubation, membranes were rinsed 3 times for 5 minutes 
in TBST before one hour incubation in horseradish peroxidase conjugated secondary antibody, 
and again rinsed 3 times.  Membranes were then incubated in chemiluminescence for 5 minutes.  
IL-6 protein bands were visualized and quantified using densitometry (Alpha Innotech; San 
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Leandro, CA).  Multiple attempts at the detection of IL-15 in practice tissue as well as subject 
samples were unsuccessful.  Thus, the analysis of IL-15 was not completed for this study. 
 Blood serum samples from each time point were analyzed using a Q-Plex Human 
Cytokine Inflammation (9-PLEX) array (Quansys Biosciences; Logan, UT).  Cytokines analyzed 
included IL-1α, IL-1β, TNF-α, IFN-γ, IL-2, IL-4, IL-6, IL-8 and IL-10.  Antigen standards were 
loaded at 1:9, 1:27, 1:81, 1:243, and 1:729 ratios of standard to sample diluent.  Serum samples 
were loaded at 1:2 ratio of sample to sample diluent.  30μl of each standard and sample were 
loaded in duplicate onto a 96 well microtiter plate.  This plate was placed on a room temperature 
shaker for one and a half hours at 300rpm.  After this incubation the plate was washed three 
times using a plate washer.  30μl of detection solution was added to each well.  The plate was 
again incubated at room temperature and 300rpm for one and a half hours.  The plate was 
washed three times using the previous plate washer program.  30μl of streptovidin was then 
added to each well.  This solution will incubate in the plate for 15 minutes at room temperature 
and 300rpm.  After this incubation the plate was washed six times.  40μl of a substrate mixture 
was added to each well.  The plate was immediately imaged for 4 minutes using the Alpha 
Innotech system (Alpha Innotech; San Leandro, CA).  The resulting images were visualized and 
quantified using densitometry (Q-View, Quansys Biosciences; Logan, UT).    
Statistical Analysis.   
Descriptive statistics were determined for subject age, anthropometric measures, and 
body composition by group.  Separate repeated measures analysis of variance (ANOVA) tests 
were conducted to examine main effects for strength, body composition, and markers of 
inflammation, as well as group interactions.  The independent variable, the subject group, 
consisted of two levels: the group placebo group and the supplement group.  The dependent 
42 
 
variables were 1-RM values for eight strength tests, weight, lean body mass and body fat, 9 
serum cytokine measures and 1 myokine measure.  The specific cytokines of interest were serum 
IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IFN-γ, and TNF-α, as well as IL-6 within skeletal 
muscle.  Four paired-samples t-tests were used to examine a main effect for IL-6 protein within 
the skeletal muscle.  Significance was determined based on an alpha level of 0.01.  This 
conservative approach was taken due to the high number of dependent variables.   
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Table 3-1:  Training Program Exercises by Day. 
______________________________________________________________________________ 
Day 1     Day 2     Day 3 
______________________________________________________________________________ 
Core Exercises: 
Squat     Dead lift    Squat 
Bench Press    Incline Press    Bench press 
Leg Extension    Bicep Curls    Leg Extension 
Leg Curl         Leg Curl 
Lat Pulldown*        Lat Pulldown* 
Accessory Exercises: 
Standing Overhead Press  Split Legged Squat   High Pull 
Weighted Sit-up   Pull-ups    Weighted Twist 
Russian Twist    Dips     Weighted V-ups 
     Weighted Supine Leg Raises 
     Weighted Wipers 
______________________________________________________________________________ 
 
*  Following week 5, Lat Pulldown was moved to the Accessory Exercises category 
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Table 3-2:  Training Volume Progression by Week and Exercise for Lower Body Core Lifts. 
______________________________________________________________________________ 
 
     Squat   Dead Lift  Leg Extension/Leg Curl 
______________________________________________________________________________ 
 
Week 1   
Sets/Reps    3/10   N/A*   2/10 
Load (%1-RM) 70%       80% 
 
Week 2 
Sets/Reps  4/10   4/10   2/10 
Load (%1-RM) 70%   70%   70% 
 
Week 3    
Sets/Reps  5/10   5/10   2/10 
Load (%1-RM) 70%   70%   75% 
 
Week 4 
Sets/Reps  3/8; 3/6†  3/8   2/8; 2/6† 
Load (%1-RM) 75%; 80%†  80%   80%; 85%†  
 
Week 5 
Sets/Reps  1-RM; 3/10**  3/10   1-RM; 2/10** 
Load (%1-RM) 70%   75%   80% 
 
Week 6 
Sets/Reps  4/10   3/10   2/10 
Load (%1-RM) 70%   75%   80% 
 
Week 7 
Sets/Reps  3/6; 3/5†  N/A*   2/6   
Load (%1-RM) 80%; 85%†     80%; 85%† 
 
Week 8 
Sets/Reps  1-RM; 3/10**  N/A   1-RM; 2/10** 
Load (%1-RM) 70%       80% 
______________________________________________________________________________ 
 
 
*   1-RM testing took place on this day for this exercise 
†   The first protocol is for Day 1; the second is for Day 3 
** 1-RM testing took place on D1 this week 
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Table 3-3:  Training Volume Progression by Week and Exercise for Upper Body Core Lifts. 
______________________________________________________________________________ 
 
     Bench    Incline   Lat Pulldown  Curls 
______________________________________________________________________________ 
 
Week 1   
Sets/Reps    3/10   N/A*   2/10   N/A* 
Load (%1-RM) 70%       80%    
 
Week 2 
Sets/Reps  4/10   4/10   2/10   3/10 
Load (%1-RM) 70%   70%   75%   80% 
 
Week 3    
Sets/Reps  5/10   5/10   2/10   3/10 
Load (%1-RM) 70%   70%   75%   80% 
 
Week 4 
Sets/Reps  3/8; 3/6†  3/8   2/8; 2/6†  3/10 
Load (%1-RM) 75%; 80%†  80%   80%; 85%†  80% 
 
Week 5 
Sets/Reps  1-RM; 3/10**  3/10      3/10  
Load (%1-RM) 70%   75%      85% 
 
Week 6 
Sets/Reps  4/10   3/10      3/10 
Load (%1-RM) 70%   75%      85% 
 
Week 7 
Sets/Reps  3/6; 3/5†  N/A*      N/A* 
Load (%1-RM) 80%; 85%†     
 
Week 8 
Sets/Reps  1-RM; 3/10**  N/A   1-RM; 2/10**  N/A 
Load (%1-RM) 70%       80% 
______________________________________________________________________________ 
 
*   1-RM testing took place on this day for this exercise 
†   The first protocol is for Day 1; the second is for Day 3 
** 1-RM testing took place on D1 this week 
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Figure 3-1:  Study Timeline. 
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CHAPTER IV 
RESULTS 
 
 The purpose of this study was to examine the effects of eight weeks of resistance training 
and supplementation on anthropometric, strength, and inflammatory changes in healthy, 
recreationally active college-aged males.  Strength and lean body mass measures were 
determined before and after the training protocol.  Muscle and blood samples were obtained 
before (PRE1) and after an acute bout of resistance training (PRE2) prior to (POST1) and 
following (POST2) the eight week training program.  Serum samples were analyzed for the 
presence of IL1-α, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IFN-γ, and TNF-α.  Muscle tissue was 
analyzed for IL-6 protein content.   
Descriptive Data 
Twenty four of the thirty recruited males completed the study (n=14 SUP, n=10 PCBO).  
Five subjects discontinued the study due to the time commitment required, while one subject was 
disqualified for missing training sessions.  Pre-training descriptive statistics for each group, 
including subjects‘ age, height (HT), weight (WT), body fat percentage (BF), and lean body 
mass (LBM) are represented in Table 4-1.   
Anthropometric Changes 
 Pre and post training mean and standard deviation values for weight, lean body mass, and 
body fat are presented in Table 4-2.  A repeated measures ANOVA revealed a significant main 
effect for weight within subjects; F (1,22) = 23.293, p < 0.01.  There was no significant group 
interaction for weight;  F (1,22) = 0.320, p > 0.01.  Similarly, a repeated measures ANOVA 
found a significant main effect for LBM measures within subjects; F (1,22) = 20.320, p < 0.01.  
48 
 
No significant interaction between SUP and PCBO was observed; F (1,22) = 0.142, p > 0.01.  
No significant differences in body fat percentage were found within subjects; F (1,22) = 1.174, p 
> 0.01; or between groups F (1,22) = 0.284, p > 0.01.  Changes in anthropometric measures can 
be examined in Figure 4-1.  Estimated marginal means for anthropometric changes within 
subjects is presented in Table 4-4.  
Strength Changes 
 Mean pre and post-training strength scores are presented in Table 4-2.  Separate repeated 
measures ANOVAs revealed significant main effects for time when analyzing the 1-RM 
measures of the squat, bench press, leg extension, leg curls, and lat pulldown exercises within 
subjects. This reveals all subjects improved their strength in those exercises.  No significant 
changes were revealed for the dead lift, incline press or bicep curl exercises.  Estimated marginal 
means within subjects for strength measures are presented in Table 4-4.  Examination of the 
changes in strength by group revealed no significant interactions for time and group in squat, 
bench press, leg extension, leg curl, lat pulldown, dead lift, incline press, or bicep curl 1-RM 
measures between SUP and PCBO groups.  The results of these statistical tests are reported in 
Table 4-3.  Graphical representation of these changes can be observed in Figure 4-2.   
Inflammatory Changes 
 A repeated measures ANOVA was used to examine differences in IL-6 within skeletal 
muscle across four time points: before the first exercise bout (PRE1); after the first exercise bout 
(PRE2); before the last exercise bout (POST1); and after the final exercise bout (POST2).  A 
significant main effect for time within subjects was found F (3,69) = 14.641, p < 0.01.  Paired 
samples t-tests revealed significant differences in skeletal muscle IL-6 content within subjects for 
PRE1 to POST1, t(23) = 4.661, p < 0.01; PRE1 to POST2, t(23) = 4.875, p < 0.01; PRE2 to 
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POST1, t(23) = 5.211, p < 0.01; and PRE2-POST2, t(23) = 6.171, p < 0.01. Changes in skeletal 
muscle IL-6 across time points are seen in Figure 4-3. The estimated marginal means for these 
time points are as follows: PRE1 18004611.48±2568563.34; PRE2 16211177.074±1617595; 
POST1 7645092.47±825379.42; POST2 6870461.19±563966.46.  There was no significant 
interaction for IL-6 protein presence and SUP/PCBO groups at any time points; F (3, 20) = 
0.586, p  > 0.01. 
Mean and standard error for serum cytokine levels across the four time points are 
presented in Table 4-6.  Statistical analyses of these levels were performed using densitometry 
values.  Mean and standard error for these values are presented in Table 4-5.  Separate repeated 
measures ANOVAs found no significant main effects for time when analyzing IL1-α, IL-1β, IL-
2, IL-4, IL-6, IL-8, IL-10, IFN-γ, or TNF-α levels within subjects; revealing no changes in serum 
cytokines in the subjects.  No significant interactions for time and groups were observed, 
suggesting the serum cytokine levels did not differ between SUP and PCBO groups.  The results 
from these analyses are presented in Table 4-7.   
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Table 4-1: Pre and Post-Training Age and Anthropometric Measures. Age is reported in years. 
WT and LBM are reported in kilograms (kg). BF is reported as a percentage of WT. *Denotes a 
significant main effect for time (p < 0.01). 
 
______________________________________________________________________________ 
 
          SUP          PCBO  
Exercise            Pre   Post          Pre        Post 
        Mean          SD       Mean          SD          Mean        SD         Mean      SD  
______________________________________________________________________________ 
 
Age   19.29    1.55        -             -    19.80   1.49        -           - 
 
Height            180.34      4.06        -             -              180.44     8.81        -           -      
 
Weight  77.90    7.21      79.57      7.54*  77.89   7.52     79.69    8.90*   
Lean Body Mass 61.70    4.13       63.25      4.03*  61.75   4.07   63.06    4.58* 
Body Fat  16.84    6.03      16.26      6.40  16.31   8.53   16.08    6.83 
______________________________________________________________________________ 
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Table 4-2:  Pre and Post-Training 1-RM Scores. 
______________________________________________________________________________ 
 
                  SUP        PCBO  
Exercise            Pre           Post         Pre        Post 
            Mean          SD     Mean          SD          Mean      SD           Mean      SD  
______________________________________________________________________________ 
 
 
Squat   112.50    21.64    145.94    23.30  107.50 22.16 135.22 20.10 
Bench Press    79.54 10.95     93.18    14.06    80.45 15.75   89.54 16.94 
Leg Extension    89.12 17.40     18.18    12.60    87.72   9.83 114.54 11.90 
Leg Curl    77.27 12.97     89.28      8.79    74.09 10.28   86.36   7.26 
Lat Pulldown    85.87 14.04     97.24    12.38    88.40 10.84   97.04   9.46 
Dead Lift  124.35 30.45     49.02    17.59  126.36 18.56 145.45 25.96  
Incline Press    75.16 13.50     82.30    12.89    72.27 11.32   80.39 15.83  
Bicep Curls    32.46   7.09     39.44      6.02    34.54   6.49   43.18   6.54 
______________________________________________________________________________ 
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Table 4-3:  Changes in 1-RM Strength Determined by Separate Repeated Measures ANOVAs. 
*Denotes a significant main effect for time (p > 0.01). No significant time x group interactions 
were observed. 
______________________________________________________________________________ 
1-RM measure          Time      Time x Group 
   F           p   F  p 
______________________________________________________________________________ 
Squat   145.604 0.000*   1.271  0.272 
Bench Press  121.069 0.000*   4.843  0.039 
Leg Extension    88.963 0.000*   0.143  0.709 
Leg Curl    47.079 0.000*   0.005  0.942 
Lat Pulldown    69.207 0.000*   1.287  0.269 
Dead Lift      4.438 0.047   2.106  0.161 
Incline Press      0.022 0.884   2.438  0.133 
Bicep Curls      0.961 0.338   3.214  0.087 
______________________________________________________________________________ 
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Table 4-4:  Pre and Post-Training Whole Muscle Estimated Marginal Means Within Subjects. 
 
______________________________________________________________________________ 
 
Measure   Pre     Post  
   Mean  SE   Mean  SE 
______________________________________________________________________________ 
1-RM 
Squat   110.41  4.39   141.47  4.53 
Bench Press    79.92  2.62     91.66  3.07 
Leg Extension    88.54  2.95   116.66  2.49 
Leg Curl    75.94  2.40     88.06  1.66 
Lat Pulldown    86.93  2.50     97.15  2.20 
Dead Lift  125.18  5.20   141.47  7.40 
Incline Press    73.95  2.50     75.66  5.30 
Bicep Curls    33.30  1.38     36.55  1.38 
Anthropometric  
Weight    77.90  1.46     79.62  1.60 
LBM     61.72  0.82     63.17  0.85 
BF     16.50  1.20     16.10  1.30 
______________________________________________________________________________ 
 
54 
 
Table 4-5:  Pre and Post-Training Serum Cytokine Densitometry Values. 
______________________________________________________________________________ 
 
Cytokine           Pre 1                    Pre 2                  Post 1              Post 2  
  
Group    Mean            SD Mean        SD            Mean   SD           Mean  SD 
______________________________________________________________________________ 
 
IL-1α 
 SUP 6617.25       6948.04         4541.59      1563.63       7335.45      9895.73          7075.07      9570.05   
 PCBO 14009.98  19738.27        10495.81    10239.08     12856.38    18982.20          9025.32      9943.96 
IL-1β 
 SUP 6512.11       8463.32        5027.79       2226.44       8343.43    16206.12          9080.32    16038.84 
 PCBO 9778.40     12499.99        8907.17       2226.44       4686.25      4964.30        11134.06    12093.84 
IL-2 
 SUP 4691.16       7765.34        4966.88       5609.76      4140.05      9222.95           5360.58    11802.77 
 PCBO 9340.48     12375.50        7873.89       8494.28      4212.15      7913.53           3508.71      5108.77 
IL-4 
 SUP 9731.62       9551.58        5764.49       1524.45      8869.24     15262.18          8959.44    14703.73 
 PCBO 9848.36       9551.58        9926.99       9059.22      9165.31       8325.87          9006.95      8843.95 
IL-6  
 SUP 4061.75       3304.51        3935.99      1423.00       7375.49     12256.46          8514.21    14693.37   
 PCBO 8840.14       9327.52        9329.54      9437.93       8674.52     14045.15          7930.89      7562.96 
IL-8 
 SUP 20706.92     9047.53      17277.20      6619.07     17897.04     11917.11        19902.60    13041.13 
 PCBO 22532.55   15783.00      20948.90    11170.10     24988.88       9001.02        24886.79      8430.56 
IL-10 
 SUP 14500.41   16659.75      13199.16    10787.46     17745.26     20694.89        19931.67    20964.14 
 PCBO 9593.77       6350.87      12820.30    11046.57     10006.73       3625.69        15324.66      9030.96 
IFN-γ 
 SUP 7436.42       6931.06        5131.08      1467.05       7960.22       9563.96          8958.59    12323.93 
 PCBO    9756.77     10423.77        8830.50      9236.71       9058.32       5570.35          9045.73      5183.85 
TNF-α 
 SUP 11440.37     6981.66        8395.79      2913.18     12463.63     15262.19        12824.64    15200.77 
 PCBO 14553.07   16218.53      12192.75    11404.57     11329.22       6136.46        12801.24      8566.89 
 
_____________________________________________________________________________________________ 
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Table 4-6:  Pre and Post-Training Serum Cytokine Levels.  Data is presented as mean ± standard 
error.  Values presented are in pg/ml.  
______________________________________________________________________________ 
               
Cytokine        Pre 1      Pre 2     Post 1     Post 2   
  
Group  Mean  SE Mean SE Mean SE Mean  SE 
______________________________________________________________________________ 
 
IL-1α  
SUP    0.00   9.70     0.00   0.20      0.04 13.95      0.00 13.49      
PCBO  46.15 27.83     21.87 14.43   38.18 26.76   11.72 14.02     
IL-1β 
SUP  32.21 12.95   21.02   3.14 45.94  24.80 51.47 24.54 
PCBO  56.69  19.13   50.16  16.62 18.52    7.59 66.86   18.50 
IL-2 
SUP                  0.00    4.72     0.00    3.41       0.00      5.61    0.00    7.18 
PCBO     2.35   7.52     0.00   5.17       0.00     4.81       0.00    3.11 
IL-4   
SUP  28.23    9.87     8.14    1.57  23.87   15.78 24.32  15.20 
PCBO  28.83    9.47   29.22    9.36  25.37     8.60 24.56    9.14 
IL-6 
SUP  10.32    3.80     9.60    1.63  29.00   14.09 35.41  16.90 
PCBO  37.25  10.72   40.01  10.85  36.32   16.15 32.13    8.69 
IL-8 
SUP  10.21    1.11     8.14    0.82    8.51     1.47   9.73    1.61 
PCBO  11.32    1.95   10.36    1.38  12.81     1.11 12.74    1.04 
IL-10 
SUP  42.15  12.74   37.27    8.25  54.31   15.83 62.50  16.03 
PCBO  23.76    4.85   35.85    8.45  25.31     2.77 45.24    6.90 
IFN-γ 
SUP  2.57    1.21     0.60    0.25    3.02     1.67   3.88    2.15 
PCBO  4.56    1.82     3.77    1.61    3.96     0.97   3.95    0.90 
TNF-α 
SUP  2.52    0.32     1.82    0.13    2.74     0.70   2.83    0.70 
PCBO  3.22    0.74     2.68    0.52    2.49     0.28   2.82    0.39 
______________________________________________________________________________ 
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Table 4-7:  Changes in Serum Cytokines Determined by Separate Repeated Measures ANOVAs. 
No significant main effects (time) or interactions (time x group) were observed (p > 0.01). 
______________________________________________________________________________ 
Cytokine           Time      Time x Group  
   F  p   F  p 
______________________________________________________________________________ 
 
IL-1α   0.624  0.608   0.667  0.582 
IL-1β   2.129  0.129   1.194  0.337 
IL-2   0.322  0.810   0.447  0.722 
IL-4   0.376  0.771   0.622  0.609 
IL-6   0.147  0.931   0.556  0.650 
IL-8   1.020  0.405   0.258  0.855 
IL-10   2.567  0.083   0.626  0.606 
IFN-γ   0.639  0.598   0.341  0.796 
TNF-α   1.737  0.192   0.216  0.884 
______________________________________________________________________________ 
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Figure 4-1:  Pre to post-testing percent change results for anthropometric measures. Data 
presented represent mean and standard error values. *Denotes a significant main effect for pre 
and post-training measures (p < 0.01).  No significant time x group interactions were observed. 
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Figure 4-2.  Pre to post-testing percent change results for 1-RM strength measures. *Denotes a 
significant main effect for pre and post-training measures (p < 0.01). No significant time x group 
interactions were observed. 
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Figure 4-3: Changes in skeletal muscle IL-6 protein content across four time points.  *Denotes a 
significant within subject difference in PRE 1 and POST 1 IL-6 content (p < 0.01). †Denotes a 
significant within subject difference in PRE 1 and POST 2, and PRE 2 and POST2 IL-6 content. 
(p < 0.01). No significant time x group interactions were observed. 
 
 
 
 
 
* † * † 
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CHAPTER V 
DISCUSSION 
 
 
 Skeletal muscle contraction has been implicated in the production of cytokines, 
specifically IL-6 (134).  This cytokine, deemed a myokine due to its production within the 
muscle, initiates a downstream cascade of changes in anti and pro-inflammatory markers.  IL-6 is 
associated with an increase in the anti-inflammatory IL-10 (35).  IL-6 and IL-10 are known to 
inhibit the pro-inflammatory markers TNF-α and IL-1β, respectively (35, 135).  Together, these 
responses significantly influence metabolism as IL-6 and TNF-α play a role in regulating glucose 
metabolism.  Prolonged endurance exercise results in an increase in IL-6 production within the 
skeletal muscle which is coupled with an increase in GLUT4 and IL-6 receptor (4, 72, 114).  
Thus, changes in IL-6 production and release in skeletal muscle have been linked to exercise 
training for those who are active and non-obese and have lower levels of resting IL-6 (40-41, 
113).  To date, the IL-6 response to an acute bout of anaerobic exercise is debated.  Few studies 
have examined the influence of resistance training on the inflammatory state including changes 
in IL-6, IL-10, TNF-α, IL-1β as well or other cytokines including IL-8, and IFN-γ.   
Resistance training studies have examined the effectiveness of supplementation of 
creatine and amino acids among other substances on strength and lean body mass changes.  No 
studies have examined the influence of these types of supplements on the inflammatory response 
to exercise.  The purpose of the present study was to determine the effects of supplementation 
and eight weeks of resistance training on strength, lean body mass, and markers of inflammation 
in recreationally active college-aged males.  Following baseline anthropometric and strength 
testing, subjects were randomized into supplement and placebo groups, and completed eight 
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weeks of total body resistance training.  Skeletal muscle biopsies and blood draws were obtained 
immediately before and after exercise day one as well as before and after the final training day in 
order to examine the tissue response to IL-6 and serum markers of IL-4, IL-6, IL-8, IL-10, TNF-
α, and IFN-γ.  Western blot analyses of skeletal muscle tissue for changes in the presence of IL-6 
protein were analyzed.  Multiplex-ELISAs were used to examine changes in serum cytokine 
levels. 
Anthropometric Changes  
 Few of the ingredients in the supplementation used in the present study have been related 
to changes in body composition; however, the combination of creatine supplementation and 
resistance training have been related to increases in lean body mass (13, 109).  Generally, past 
training studies that have elicited these positive results are associated with a creatine loading 
phase of up to 20g/day for 5 days followed by 5-10g/day for several weeks of training (13, 109).  
Training and creatine supplementation are generally not associated with changes in overall body 
fat percentage (13, 56, 85, 90, 143).  The present study elicited increases in lean body mass in all 
subjects, suggesting these changes were a result of the resistance training, and the 
supplementation protocol did not play a role in this increase.  It is likely that the lack of a 
creatine loading phase, or the smaller dose of creatine within the supplement was not enough to 
elicit greater changes in the SUP group.  Similar to previous studies, no significant differences in 
body fat were seen in either subject group.  The anthropometric findings of this study support the 
proposed hypothesis that eight weeks of resistance training would elicit improvements in lean 
body mass in all subjects without significant differences between SUP and PCBO groups.   
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Strength Changes  
Previous studies have examined the use of common supplement ingredients including 
caffeine, creatine, and amino acids.  Most caffeine supplementation studies have focused on the 
acute exercise response and have shown improvements in aerobic performance with conflicting 
results on anaerobic performance.  Caffeine supplementation of 5-6mg/kg body weight has been 
associated with increases in peak power and reduced fatigue (149).  Other studies have shown no 
changes in 40-yd dash, 20-yd shuttle, 1-RM leg or bench press, or endurance bench press tests 
following consumption of similar doses of caffeine (7, 11, 92, 150).  No studies to date have 
reported the effect of caffeine supplementation on a resistance training program.  Unlike caffeine 
supplementation, creatine supplementation of 1.25g/day to 10g/day has shown improvements in 
strength, power, and reduced fatigue (13, 56, 85, 90, 143).  Many amino acids including arginine, 
glutamine, arginine, and taurine, are also commonly supplemented.  A previous study revealed 
an intake of 6g of L-arginine and 6g of alpha keto-glutarate per day for 8 weeks was associated 
with increases in 1-RM bench press and power determined by Wingate testing (22).  Other 
studies suggested a smaller 3g/day dose decreased plasma lactate and increased L-citrulline with 
in the blood (124).  Despite these positive changes in past studies, the supplement studied in the 
present project contained only 1.742g of a combined arginine-alphaketoglutarate.  Similarly, the 
supplement contained 1g of N-Acetyl L-Glutamine, while past studies have suggested much 
higher doses of 0.9g/kg of LBM combined with six weeks of resistance training result in 
significant increases in strength and LBM (6).  Previous research has also demonstrated doses of 
3.2g/day to 6.4g/day of alanine are associated with increases in intramuscular carnosine, which 
effective in pH buffering and the regulation of calcium sensitivity (55).  The supplement used in 
the present study contained 1.5g of beta-alanine.   
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The small dose of each of these ingredients within the supplement may provide an 
explanation for the results of the present study.  While significant increases in squat, bench press, 
leg extension, leg curl, and lat pulldown, were found across all subjects, there were no significant 
differences in strength between SUPP and PCBO groups for any strength measure, supporting 
the original hypothesis.  While these ergogenic aids have elicited positive effects on exercise 
performance in the past, the low doses of each within the pre-workout supplement may not have 
been enough to stimulate effects on performance greater than that of resistance training alone.  
No significant differences in dead lift, incline press, or bicep curl 1-RM strength were found 
across subjects.  It is likely that this was because these exercises were performed once a week, 
while the squat, bench press, leg extension, leg curl, and lat pulldown exercises were performed 
twice per week.       
Inflammatory Changes  
 Previous research on the influence of resistance training on markers of inflammation is 
scarce.  To date, no studies have examined the influence of a pre-exercise supplement and 
resistance training program on the cytokine response within skeletal muscle tissue or the 
systemic response within serum.  The present study revealed significant changes in skeletal 
muscle IL-6 protein content were observed following eight weeks of training.  Basal levels of IL-
6 following the training program were significantly lower than both basal and post-exercise pre-
training values.  These findings are in contrast to the original hypothesis which suggested IL-6 
protein concentration would be greater following eight weeks of resistance training.  In addition, 
no previous studies have examined changes in IL-6 protein content within skeletal muscle 
following a resistance training program.  Despite this, the information obtained from the present 
analysis is consistent with previous studies of aerobic training that found reduced gene 
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expression of IL-6 following training (42).  This previous analysis revealed an increase in IL-6 
receptor following training is likely the cause in reduced protein expression.  It is possible that 
regular resistance training might also increase IL-6 receptor mRNA, thus reducing IL-6 protein 
presence within the skeletal muscle following training.   
Despite this training effect, no significant differences in IL-6 protein were observed 
following an acute bout of exercise.  This too is in contrast to the original hypothesis as previous 
studies of prolonged aerobic exercise that have revealed acute exercise increases IL-6 and IL-6 
receptor mRNA expression (72).  Studies examining changes in skeletal muscle IL-6 have 
debated whether changes in this protein are associated with exercise intensity, duration, type of 
exercise or musculature associated with the exercise (108).  Some have suggested only exercise 
lasting more than one hour has been shown to elicit 10-fold increases in IL-6 protein (112). This 
research suggested running has elicited the greatest IL-6 response; however, as mentioned few 
studies have examined the IL-6 response to resistance training.  While it is possible that the 
exercise bout was not long enough to elicit a significant increase in IL-6 protein within the 
musculature, it is more likely that the exercise specifically focusing on the vastus lateralis 
muscle, the muscle that was sampled, was not long enough in duration to elicit a response.  In 
addition, since these exercises (squat, leg extension) were performed within the first fifteen 
minutes of the exercise bout, and little is known about the time frame associated with increases 
of IL-6 protein within the muscle in response to resistance training, it is possible the production 
of this protein may have peaked prior to the muscle sampling.  While conflicting studies exist, 
most of those examining the skeletal muscle production of IL-6 protein following aerobic 
exercise have determined IL-6 peaks immediately following exercise of the vastus lateralis 
muscle (running, cycling) (105, 133, 139).   
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The present study also revealed that an acute bout of exercise did not significantly alter 
the systemic inflammatory state in recreationally trained individuals, or the same individuals 
following an eight week resistance training program.  These findings support the original 
hypothesis as there were no significant differences in serum IL-1α, IL-β, IL-2, IL-4, IL-6, IL-8, 
IL-10, IFN-γ, or TNF-α at any of the four time points.  Previous literature has indicated that the 
increase in plasma IL-6 that accompanies exercise is due to significant increases in the skeletal 
muscle production of IL-6 (134).  The fact that in the present study there was not a significant 
increase in skeletal muscle production of IL-6 can explain the changes, or lack thereof, within 
the serum inflammatory markers.  Since changes in many of the other cytokines including IL-10, 
TNF-α, and IL-1β are related to the presence of IL-6, the absence of changes in IL-6 could 
indicate why no significant differences in these measures were observed.  It is possible that the 
recreationally trained state of the subjects may have limited the changes in cytokines seen 
following an acute bout of exercise.  Studies of aerobic exercise have revealed serum levels of 
IL-6 increase significantly more in untrained subjects (50).   
Izquierdo et al. (69) also did not find significant differences in serum IL-1α, IL-β, or IL-
10 following an acute bout of lower body resistance exercise in previously trained individuals.  
However, these authors reported significant increases in IL-6 at 45 minutes following an acute 
exercise bout as well as increases in post-exercise markers of -1α, IL-β, IL-6 and IL-10 following 
seven weeks of resistance training.  Differences between this data and the present study can be 
explained by differences in the testing protocol.  In the present study, blood samples were 
obtained immediately before and after a whole-body resistance training program lasting 
approximately one hour.  Izquiredo et al. (69) collected blood samples at various time points 
before and after five sets of 10 repetitions of the leg press exercise.  Previous studies have 
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reported exercises that focus on a smaller area of muscle mass may result in a significant 
increase in serum IL-6 (58, 101, 137); thus, the lower body only testing protocol may be 
responsible for the differences in serum IL-6 and IL-10 content between the two studies.  Also, 
while IL-10 was significantly higher than baseline during, immediately after, and at 15 and 45 
minutes post exercise in the previous study, IL-6 was only significantly higher at 45 minutes post 
exercise.  It is possible that during the present study this peak in IL-6 was not seen due to the 
lack of increases in muscular IL-6 protein production as previously discussed, or possibly due to 
the immediate post exercise blood draw.  This time point was chosen as few studies had 
examined the cytokine response to resistance training.  Previous studies had revealed an increase 
in IL-6 immediately following anaerobic sprint intervals (95), and most aerobic training studies 
suggested IL-6 peaked immediately following exercise and gradually declined during exercise 
recovery (105, 132).  Still others have found results similar to those of the present study, 
reporting no significant changes in serum IL-6 following circuit weight training (18) or 
following short bouts of maximal resistance exercise (138).  
 Several in vitro studies have examined the influence of caffeine on the cytokine response.  
These studies have suggested caffeine reduces TNF-α in human blood mononuclear cells, 
adipose cells, and IL-6 and TNF-α in mouse models (36, 66).  Similarly, glutamine 
supplementation has been associated with decreases in TNF-α in vitro (149).  This amino acid 
has also been shown to assist in maintenance of force production during acute IL-6 and TNF-α 
inflammation (96).  Vitamin E, which is an ingredient in the supplement in the current study, 
might also have a positive role in inflammation as it has been shown that 800IU/day is associated 
with decreased IL-1β production following a downhill running bout (94).  Other in vitro studies 
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have suggested this vitamin decreases IL-6 and IL-1β (68).  In the present study no significant 
differences between SUPP and PCBO groups were observed for serum inflammatory markers. 
While previous studies have suggested caffeine (36, 65) glutamine (97) and Vitamin E (96, 68) 
might positively affect these markers by reducing pro-inflammatory cytokines, this is the first 
study to examine the effect of pre-workout supplementation on these markers.  It is possible, as 
suggested previously, that the doses of glutamine and Vitamin E within the supplement 
investigated in this study were not high enough to illicit an effect on the production of cytokines. 
Despite this, it is difficult to suggest the same is true for caffeine as the dose of this ingredient 
was approximately 5.8g/kg of body weight for the average subject weight.  It is unknown how 
this dose compares to previous in vitro studies.  Further studies are necessary to examine the in 
vivo effect of caffeine consumption on resistance training programs as well as the cytokine 
response in humans. 
Summary 
 The complex cytokine signaling that occurs as a result of skeletal muscle contraction has 
been extensively studied.  Many of these studies have suggested the duration, intensity, and type 
of exercise performed will influence the extent of inflammatory changes following exercise, 
however still little is known about what causes these changes.  To date, most literature has 
focused on the impact of prolonged aerobic exercise on cytokine signaling.  These studies 
suggest IL-6 release from the skeletal muscle increases following an acute bout of exercise and 
are directly supported by an increase in plasma IL-6, IL-10, IL-15, decreases in IL-1β and TNF-
α, and increases in IL-8 within the skeletal muscle.  Studies of aerobic training have suggested 
that regular training reduces skeletal muscle IL-6 mRNA expression, possibly due to an increase 
in IL-6 receptor within the skeletal muscle.  Other than the present study, no studies have 
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examined the skeletal muscle inflammatory response to resistance training.  This study suggested 
an acute bout of total body resistance training does not elicit significant increases in skeletal 
muscle or serum IL-6, or serum IL-1α, IL-1β, IL-2, IL-4, IL-8, IL-10, IFN-γ, or TNF-α.  These 
findings do not support the hypothesized response to an acute bout of exercise, or to the training 
program. 
 As discussed, it is possible these findings differ from similar studies which have 
examined the inflammatory response of serum markers because of the type of exercises 
employed, the time points at which samples were collected, or the training state of the subjects.  
The subject pool, specifically their training history and their caffeine consumption prior to the 
study are also considered limitations to the present study.  These variables were examined using 
a self-report prior to subject selection.  It is possible if the subjects were not honest with their 
answers to these surveys that the fitness level and/or tolerance to caffeine may have been 
different than intended and thus affected the outcome of the study.   
Little is known about the skeletal muscle IL-6 production during resistance training.  
Because of this, it is possible that the time at which muscle samples were collected could also be 
a limitation of this study.  In addition, even less is known about the effect of pre-workout 
supplementation on the inflammatory response.  While many of the ingredients within the 
supplement tested might have a role in changing inflammation, these ingredients should be tested 
individually and not as a mixed supplement in order to fully understand their role on the 
inflammatory response.   
 It is also possible that the muscle biopsy itself may have altered the inflammatory 
response within either the skeletal muscle itself or within the systemic response.  However, since 
the percutaneous biopsy technique is the best method for obtaining human skeletal muscle 
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samples and the same procedures were used for each biopsy, it was assumed this inflammatory 
response was similar in each case.  In order to ensure any changes seen within the skeletal 
muscle itself were due to the exercise bout and not a local inflammatory response, biopsies 
performed on the same day were performed on opposite legs.   
Following the biopsy process as well as during protein analyses all samples were handled 
in a manner aimed at limiting any degradation or contamination of proteins.  All gels and 
solutions used in the Western Immunoblotting and ELISA processes were made fresh to 
eliminate contamination as well as ensure the same protocols for the analysis of each sample.  
The Western Immunoblotting process is commonly used for the analysis of proteins within 
skeletal muscle and had previously been used for the analysis of IL-6 within this lab.  The use of 
the Multiplex ELISA for analysis of markers of inflammation was relatively new to this lab; 
however, several practice samples were tested using this methodology to ensure proper detection 
of proteins. 
Practical Implications 
 The present study has demonstrated the cytokine response to acute and chronic resistance 
training is likely different than the inflammatory response to aerobic exercise.  Despite this, 
changes in basal skeletal muscle IL-6 reveal the potential for a training effect following eight 
weeks of resistance training.  In addition, the use of a multi-ingredient supplement did not 
significantly change markers of inflammation this college-aged, recreationally active population.  
Further analysis of the inflammatory changes that occur following acute resistance exercise and 
chronic resistance training are warranted.  These studies could provide useful exercise training 
insight for individuals suffering from diseases related to altered inflammatory profiles. 
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 This study also examined the use of a multi-ingredient supplement prior to resistance 
training exercise on changes in strength and lean body mass.  While many previous studies have 
found ingredients within the supplement effective in improving LBM and 1-RM strength 
measures, this study has revealed the combination of these ingredients may not result in the same 
positive performance outcomes.  It is possible the dose of each ingredient within the supplement 
was lower than those previously reported to promote such changes.  
Implications for Future Research 
 The cytokine signaling network is very complex and thus allows for many directions of 
research.  It is important to continue to examine the cytokine response to exercise as changes in 
inflammation following regular training programs might provide effective means of controlling 
diseases marked by an altered cytokine state such as type II diabetes.  Because much research 
has focused on aerobic exercise, further studies should examine the cytokine response to 
resistance exercise in both active and inactive individuals.  Further examination of the 
inflammatory response to supplementation in vivo using separate studies for each ingredient 
within the supplement, and higher doses of each ingredient used could also provide insight to 
possible pharmacological interventions for diseases associated with cytokine disturbances. 
Conclusions 
 The eight weeks of resistance training implemented in the present study resulted in 
expected changes in strength and lean body mass.  Analysis of the tissue collected suggested an 
acute bout of total-body resistance exercise does not significantly increase skeletal muscle IL-6, 
however decreases in IL-6 with regular resistance training were reported and are in accordance 
with previous findings following aerobic training.  Contrary to other studies acute or regular 
resistance exercise training did not result in any significant alterations of the inflammatory 
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markers IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IFN-γ, or TNF-α.  In addition a pre-workout 
supplement containing caffeine, creatine, and amino acids among other ingredients did not 
significantly affect strength, lean body changes, or markers of inflammation associated with 
regular resistance training.      
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Effects of Resistance Exercise and a Pre-Workout Dietary 
Supplement on Physiological Adaptations 
 
Informed Consent 
 
INTRODUCTION 
You are invited to participate in a research study examining the effectiveness of a pre-workout 
dietary supplement combined with resistance exercise on various physiological variables. Thirty 
subjects are being sought to participate in this study at the University of Kansas. The Department 
of Health, Sports, and Exercise Sciences at the University of Kansas supports the practice of 
protection for human subjects participating in research.  The following information is provided to 
help you make an informed decision on whether or not to participate in the present study. Please 
feel free to ask any questions.  This study was requested and is funded by Labrada Nutrition Inc. 
 
PURPOSE OF THE STUDY 
The purpose of this study is to examine the effectiveness of a pre-workout dietary supplement 
combined with an 8-week resistance training program on physiological measures.  This 
supplement contains large amounts of caffeine (450mg); the equivalent of 4.5 cups of coffee.  
The supplement is not currently commercially available and is not approved by the Food and 
Drug administration (FDA), as no supplements are approved by the FDA.  Aside from examining 
the effectiveness of the supplement, the resistance training component of this study could 
provide information concerning the role of resistance training in preventing and treating various 
disease states associated with inflammation and muscle wasting. The physiological variables that 
will be measured include body weight, body composition, strength and power, as well as blood 
and muscle markers of skeletal muscle growth (hypertrophy) and the inflammatory response to 
training. Psychological variables of interest include body image, effort and enjoyment of 
training, and happiness from pre- to post-study. The findings of this study will determine if the 
use of this pre-workout supplement in addition to an 8-week training plan results in changes in 
weight, lean body mass, muscular strength and hypertrophy that are different from the changes in 
these variables that result from the 8-week training plan alone.   
 
BASIS FOR SUBJECT SELECTION 
In order to participate in this study you must be male, between the ages of 18 and 35, healthy, 
non-obese (BMI <28 kg/m
2
), non-smoking, and free of metabolic, cardiovascular, kidney 
diseases, as well as free of a history of seizures. You will be screened for participation using a 
health-history questionnaire for contraindications to exercise by American College of Sports 
Medicine (ACSM) guidelines. If you are currently taking any medications or supplements that 
may interact with ingredients in the supplement/placebo involved in this study you will be 
excluded from the study.  In order to participate in this study you must be recreationally trained 
(exercise 3 or more days / week for at least 1 year) in order to mimic those who are generally 
Approved by the Human Subjects Committee University of 
Kansas, Lawrence Campus (HSCL).  Approval expires one year 
from 9/24/2009. HSCL#18136 
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more likely to use a supplement of this kind. In addition, if you currently use drugs that reduce 
inflammation (aspirin, ibuprofin, NSAIDs, etc.) on a regular basis you will be excluded from this 
investigation. You will also be asked to refrain from using these drugs during the course of this 
study.  Due to gender differences in hormonal fluctuations and responses to resistance training 
only males will be recruited. The inclusion criteria is listed below: 
 
Inclusionary Criteria 
 
 Male 
 Over the age of 18 
 Under the age of 35 
 Meets activity requirements (exercise 3 or more days per week for at least 1 year) 
 Non-Obese (BMI <28 kg/m2) 
 Non-Smoker 
 Has not experienced adverse effects to caffeine despite regular ingestion (including but 
not limited to dizziness, lightheadedness, nausea, ‗jitters‘) 
 Does not use anti-inflammatory medications or over-the counter drugs or can discontinue 
for the course of the study 
 Does not uses other nutritional supplements or will discontinue for the course of the study 
 Does not take other medications that may interact with ingredients in the placebo and/or 
supplement (including but not limited to anti-asthmatic medications, anti-hypertensive 
medications, blood thinners, anti-seizure medications, anti-anxiety medications, 
monoamine oxidase inhibitors-MAOIs) 
 No history of any of the following: myocardial infarction, angiography, coronary surgery, 
chest discomfort, high blood pressure, low blood pressure, shortness of breath upon light 
exertion, pulmonary disease, dizziness upon light exertion, heart palpitation, heart 
murmur, diabetes (I or II), circulation problems, stomach ulcers, kidney problems, metal 
implants, seizures 
 No history of allergies to local anesthetics 
 No history of allergies to iodine 
 No history of allergies to Band-Aids or other adhesives 
 No history of food allergies (including but not limited to ingredients in the placebo such 
as polydextrin or mannitol, or ingredients in the supplement such as caffeine, tyrosine, 
citrulline, malate, arginine, taurine, creatine, betaine, picamilon, niacin, beta-alanine, 
glutamine, histidine, vitamin A or vitamin E, food coloring) 
 No history of computed tomography (CT), PET, fluoroscopic, or nuclear medicine 
studies within the past year. 
 
PROCEDURES 
A time-line of the testing procedures and an overview of the training program for the present 
study are presented below.  All procedures will be conducted in the Applied Physiology 
Laboratory (APL) at the University of Kansas and will be supervised by trained personnel.  It is 
important for you to note that this study will require your presence in the Applied Physiology 
Laboratory for three exercise sessions per week (approximately five hours per week) for eight 
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weeks, as well as two testing sessions for one week prior to the start of the training program 
(approximately 2.5 hours). 
 
Timeline of Procedures for Control and Experimental Groups: 
 
Pre-Screening: 
 All subjects 
 Health History Questionnaire 
 Pre-Biopsy Screening Questionnaire 
 Physical Activity Questionnaire 
 Caffeine Intake and Tolerance Questionnaire 
 Body image, effort and enjoyment of training, and happiness surveys 
 Body Weight, Anthropometric Tests, Body Composition Testing using DEXA 
Scan  
  
Testing Week 0, Day 1: 
 1-Repetition Maximum (RM) on all exercises in the training protocol 
 
Testing Week 0, Day 2 (3 days after Testing Day 1): 
 Power Testing for Bench Press and Back Squat (70% 1-RM); Vertical Jump Test 
 Rate of Force Development Testing Using an Isometric Bench Press 
  
Training Week 1, Day 1: 
 Report to the APL following an 8 hour fast 
 Turn in 3-day dietary recall 
 30 Minute Rest 
 Blood Draw #1, Biopsy #1 
 Drink Supplement/Placebo 
 Exercise Session 
 15 Minute Rest  
 Blood Draw #2, Biopsy #2 
 
Training Week 5, Day 1: 
 Body Weight Testing 
Strength Testing (1-RM) on all exercises in the training protocol will be 
substituted for normal workout. 
 
Training Week 5, Day 2: 
 Power testing for bench press and back squat (70% 1-RM); vertical jump test 
 Rate of force development testing using an isometric bench press 
These tests will be incorporated with the bench press and squat sessions within 
the normal workout. 
 
Training Week 8, Day 1: 
Strength Testing (1-RM) on all exercises in the training protocol will be 
substituted for normal workout. 
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Training Week 8, Day 2: 
 Power Testing for bench press and back squat (70% 1-RM); vertical jump test 
 Rate of force development testing using an isometric bench press 
These tests will be incorporated with the bench press and squat sessions within 
the normal workout.  
 Body image, effort and enjoyment of training, and happiness surveys 
 
Training Week 8, Day 3: 
 Report to the APL following an 8 hour fast 
 Turn in 3-day dietary recall 
 30 Minute Rest 
 Blood Draw #3, Biopsy #3 
 Drink Supplement/Placebo 
 Exercise Session 
 15 Minute Rest 
 Blood Draw #4, Biopsy #4 
 DEXA Scan 
 
Week 0 1 2 3 4 5 6 7 8 9 
Supplement  
 
        
 
Training 
 
Biopsy 
 
Blood Draw 
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Body 
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Side Effect 
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1) Pre-testing Protocol – Health history, physical activity, caffeine intake and tolerance, body 
image, effort and enjoyment of training, and happiness, and pre-biopsy questionnaires, and 
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anthropometric data will be obtained approximately 1 week prior to Testing Day 1.  These 
procedures will take approximately 1 hour. The DEXA scan uses an FDA-approved X-ray 
absortiometry machine to examine body composition (relative amounts of fat mass and lean 
body mass).  During this test you will be asked to lie face up and motionless on a padded table 
for 7-15 minutes while the scanner arm of the DEXA machine passes over your entire body.  The 
scanner will not enclose or touch you, and you can wear your regular clothing (no metal or 
jewelry allowed).  The DEXA scan information is being used solely for descriptive and 
comparison purposes.  This information is not intended to be used as a clinical assessment of any 
medical conditions. 
 
2) Exercise Testing - All strength testing will be done using free weights or weight machines 
and following standard repetition maximum strength testing guidelines. You will be asked to 
warm-up for five minutes using a stationary leg cycle.  Following this you will perform warm-up 
sets followed by maximal effort lifts for each of the following exercises:  back squat, bench 
press, lat pull-down, barbell lunges, leg extension and curl, bicep curls, standing shoulder press, 
pull-ups, and dips.  Three days later you will return to the lab and perform power tests for the 
bench press and the back squat.  This will involve a warm-up, followed by a set of 10 repetitions 
at 70% of your bench press and back squat maximum.  Following this you will perform a rate of 
force development test for the bench press and leg extension exercises. Force transducers will be 
placed in-series with the resistance cable to detect isometric force for these exercises.  For this 
test you will begin to perform the exercise as normal by generating force to move the weight, 
however the weight will be fixed and will not move.  Following this test you will perform three 
maximal vertical jumps with approximately 3 minutes of rest between each.  This will allow for 
the calculation of lower body power. 
 
3)  Dietary Recall – All subjects will be asked to record food and drink consumption (including 
portion sizes) for three consecutive days prior to their first (training week 1, day 1) and last 
muscle biopsies (training week 8, day 3).  Subjects will be given an explanation of portion sizes 
prior to completion of the dietary recall. 
 
4) Supplementation – All subjects will be asked to consume either a supplement or placebo 
drink 15 minutes prior to each exercise session. The supplement/placebo mix containers will be 
labeled as either A or B, however the experiment will be double blind in nature as neither the 
research staff nor the subjects will know which drink is the placebo and which is the supplement.  
An individual associated with the Applied Physiology Lab, but not directly involved in this 
research project, will be assigned the duty of randomizing subjects into placebo and supplement 
groups. They will also be responsible for mixing the supplement drinks, and monitoring the 
subjects as they consume the supplement.  As this experiment is double blind, no other 
individuals associated with the study (research staff or subjects) will know which mix is the 
supplement and which is the placebo until after the study is completed.   Questionnaires will be 
provided to you at each exercise session to record any adverse effects you might have as a result 
of taking the placebo or supplement.   
 
5) Exercise Training – All subjects will report to the lab for training three times per week for a 
period of eight weeks.  These training sessions will be supervised by Applied Physiology 
Laboratory personnel.  All subjects will complete an exercise program consisting of the 
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following exercises:  back squat, bench press, lat pull-down, barbell lunges, leg extension and 
curl, bicep curls, standing shoulder press, pull-ups, and dips.  The training program will be 
relative to each subject and exercise will be prescribed as a percentage of their 1-RM on each 
exercise.  We will also ask you to fill out a pre/post exercise survey to asses your anticipation of 
training, recovery, strength, and muscle pain. These surveys will take less than 5 minutes to 
complete.    Subjects are asked to refrain from exercise other than that which is prescribed by this 
study and takes place during the assigned lab training hours. 
 
6) Muscle Biopsies – You have been informed that one of the purposes of this study is to 
measure the cellular markers of muscle growth and inflammation from the muscle samples that 
we collect.  By obtaining a small sample of your muscle tissue (size of a pencil eraser or small 
finger nail), the different types of proteins in your muscle may be determined which will be 
helpful in the evaluation of health and exercise performance.  All muscle tissue samples 
(biopsies) will be taken from the outer portion of the front of the thigh using a needle biopsy 
technique by either Philip Gallagher or Andy Fry.  Philip Gallagher, PhD., Assistant Professor of 
HSES, and Andy Fry, PhD., Professor of HSES, have performed over 200 muscle biopsies over 
the past year and have assisted on over 1000 biopsies over the past six years on various 
populations (athletes, sedentary people, elderly etc.) with no significant complications and 
nothing more than minimal adverse reactions. The procedure is being overseen by Jeff Burns, 
M.D., who is a medical doctor in Neurology at the KU Medical Center in Kansas City, Kansas.  
Dr. Burns supervises the procedure, but will not be physically present for the biopsies.  The total 
size of the muscle biopsy will be approximately the size of a pea. You will be placed on an 
examination table lying down on your back (supine) so that the muscles of the leg are relaxed.  
The skin will be thoroughly cleaned with antiseptic solution (Betadine) using sterile cotton 
swabs after which a surgical cover will be placed around the sampling site. If you are allergic to 
Betadine, an alternative antiseptic solution will be used to clean the skin. A small amount (2ml or 
2cc) of a local aesthetic (2% Lidocaine) will be injected into the tissue under the skin around the 
site to be sampled. During this injection you may feel a slight burning sensation. If you are 
allergic to the local anesthetic, or have had allergic reactions to other anesthetics (i.e.: Novocain) 
then you will be disqualified from the study. Following the injection of the numbing agent into 
your thigh, a minimum of five (5) minutes will be allowed to pass to ensure adequate time for the 
agent to take effect in the area where the incision will be made. A small incision (1 cm) will then 
be made in the skin overlying the muscle and the biopsy needle inserted into the middle of the 
muscle (muscle belly) at a depth of 3 cm (about 1 inch). During the time that the sample is being 
taken (about 5 seconds) you may feel some deep pressure and cramping that will be moderately 
painful. You have been informed that if you have been previously diagnosed as having a 
bleeding disorder, a blood clotting problem, take blood thinning medication or have sensitivity to 
scarring, you will tell the researcher and not participate in the biopsy procedure.  
Following the biopsy procedure, firm and constant pressure will be placed on the wound to stop 
any bleeding. The incision site will be closed with a Steri-Strip and covered with a large Band-
Aid and the site compressed using a 10 cm strip of sterile elastic surgical stocking for a period of 
24-hrs.  You have been informed that the procedure will take about 20 min.  
Sterile disposable instruments and sterile gloves will be used for the preparation of the site and 
the reusable biopsy needle will be thoroughly sterilized (via steam and heat autoclave) after each 
biopsy.  Approximately 100 mg (size of a pencil eraser or small finger nail) of skeletal muscle 
tissue will be removed. With the invasive skeletal muscle biopsy technique there is the 
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possibility of a blood related infection (HIV, Hepatitis B), but the reusable needles will be 
cleaned and sterilized using an autoclave, a generally accepted method of cleaning surgical 
instruments.  
A total of four (4) biopsies will be performed over the course of the study (see timeline, above). 
 
7) Blood Draws – We will measure hormonal markers as well as levels of inflammation found in 
your blood prior to and following the first and last exercise bouts.  Four blood draws will be 
performed during this study (see timeline, above).  In this procedure, a small amount of blood 
will be taken from a vein for each blood draw by a trained phlebotomist using a needle and a 
syringe.  Approximately 10 cc of blood (~ 2 teaspoons) will be drawn for each time-point.  The 
blood draw will take about 5 minutes. 
 
RISKS 
 
1) DEXA scan – The examination of fat and lean body mass using the DEXA scan involves the 
use of X-rays.    Any time an individual is exposed to radiation there is a potential risk.  The 
University of Kansas has adopted the philosophy of safety that all exposures to radiation, other 
hazardous materials, and risks from physical hazards shall be kept ―as low as reasonably 
achievable.‖  There are certain limitations placed upon this procedure to achieve that aim.  We 
also want to evaluate the amount of radiation that you have received in the past year, so if you 
have had other X-rays, let us know.  If you have recently undergone CT (Computed 
Tomography), PET, fluoroscopic, or nuclear medicine studies within the past year, you cannot 
participate in the study.  The part of your body that will receive the most radiation is the skin, 
although your whole body will be exposed to the radiation.  The amount of radiation that you 
will receive from a whole body scan is the equivalent to a uniform whole-body exposure of 0.1 
mrem.  Although you will be receiving a small amount of exposure, the risk from radiation 
exposure of this magnitude is too small to be measured directly and is considered to be negligible 
when compared with other everyday risks.  For example, you would receive radiation exposure 
of approximately 80 mrem on a transatlantic airline flight of 8 hours, or 30-40 mrem during a 
typical chest x-ray.  The Radiation Safety Officer at the University of Kansas can provide you 
with more information about radiation exposure if you are interested.  The DEXA measurements 
are being made by trained personnel who have either received accreditation from the 
International Society for Clinical Densiometry for diagnostic procedures, or who have received 
formal training by the manufacturer following installation of the DEXA for femur/spine/total 
body scans.  The system is equipped with a Class II Laser device.  A Class II rating indicates a 
low power visible laser that is not normally hazardous to eyesight but has the potential to be 
hazardous if viewed directly for an extended period of time.  Because of the potential hazard DO 
NOT stare directly into the beam while the laser is in operation.  The beam should not be pointed 
directly in the eye of the participant. 
 
2) Muscle biopsies – The use of local anesthetics will result in a slight burning sensation, lasting 
approximately 5 seconds. There is a risk of allergic reactions to the local injection (1 in 1 
million). There is a small chance of bleeding from the biopsy site. The principle concern would 
be prolonged bleeding which would produce a bruise in the area. This would extend the muscle 
soreness, but is adequately treated with rest, ice, a compression bandage, and keeping the leg 
elevated as much as possible. Nausea, dizziness, and fainting can occur (1 in 100) during the 
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biopsy process. As a result, the subjects will be in a supine position during the biopsy procedure. 
There is a risk of infection (1 in 1000) and irritation associated with the biopsy procedure. The 
use of aseptic techniques, careful cleaning of the skin and keeping the area dry will minimize the 
risk of infection.  There is a risk of bruising (1 in 100) from the biopsy procedure. This will be 
minimized by placing ice over the site following the procedure and by applying a compression 
bandage on the site for the 24 hours following the biopsy. In some instances (1 in 200), some 
motor nerves may be damaged which may cause local muscle atrophy (decrease in the size of 
muscle fibers, with a small dimple on the skin). There is likely to be a small scar where the 
biopsy is performed. This scar usually dissipates over a period of 6-12 months at which time the 
scaring is very modest. 
 
3) Blood Draws – The blood sample has a small risk of infection and bruising of the area. The 
needle stick for the blood draw will be mildly painful and only lasts a couple of seconds. 
 
4) Supplement/Placebo—You will be asked to ingest a supplement or a placebo drink fifteen 
minutes before each training bout.  This variation of the supplement is not currently available for 
commercial sale and is not approved by the Food and Drug Administration (FDA), as no 
supplements are approved by the FDA.  The ingredients found in this supplement and 
information concerning the safety of their ingestion is listed below.  An extended version of this 
information is attached as an appendix and we encourage you to read that as well.    In addition, 
blood pressure will be monitored once each week prior to supplementation in order to ensure 
your body is not having an adverse reaction to the caffeine in the supplement.  These 
questionnaires and blood pressure measures will be reviewed by the safety monitoring board. 
Due to the possibility that other supplements may contain similar ingredients that might interact 
with ingredients in the study placebo/supplement and place you at risk or  confound the results of 
this study, you are asked to refrain from using all other nutritional supplements or ergogenic aids 
during the course of this study.  
 
Placebo: 
The placebo drink will consist of a low-glycemic flavor and color matched drink sweetened 
with polydextrin and/or mannitol.  Persons known to be allergic to one of the ingredients will 
be excluded from the study 
 
Supplement: 
Caffeine. The experimental exercise supplement contains 450 mg of caffeine.  This amount is 
the equivalent of 4.5 eight ounce cups of coffee.  Caffeine is a known stimulant and diuretic. 
Side effects of caffeine ingestion can include increased mental concentration, increased 
physical work capacity, ‗jitters‘, nervousness, and dizziness or light headedness. These 
symptoms increase with the amount of caffeine consumed so we ask that you refrain from 
consuming more than one additional serving of caffeinated beverages per day, (coffee, tea, 
energy drinks, colas) during the study.  You will be included in this study if you have 
previously consumed moderate amounts of caffeine (300mg/day or more) without experiencing 
any uncomfortable negative side effects.   
 
L-Tyrosine.  The supplement contains 500 mg of L-tyrosine.  Tyrosine a non-essential amino 
acid (meaning the body is capable of producing it from other nutrients) commonly found in 
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meats and dairy products.    Doses of 100 to several thousand mg of L-tyrosine are common.  
Overconsumption of tyrosine (which is unforeseeable in this study) can cause gastric upset, 
diarrhea, and migraine headaches.   
 
L-Citrulline-di-malate. The supplement used in this study contains 1000 mg of L-citrulline-di-
malate, an amino acid derivative. Previous research using citrulline in greater doses than the 
present study did not cause any adverse side effects in men, therefore we do not anticipate any 
risks to you due to this ingredient.  
 
Arginine Alpha-ketogluterate.  The supplement contains 1742 mg of arginine alpha-
ketogluterate, another naturally occurring amino acid derivative.  Previous research using 
arginine alpha-ketogluterate in greater doses than the present study did not cause any adverse 
side effects in men, therefore we do not anticipate any risks to you due to this ingredient.  
 
Taurine. The supplement contains 1,000mg of taurine, an amino acid derivative found 
naturally in protein rich foods. The recommended amount of taurine supplementation (beyond 
food sources) should not exceed 3,000mg per day.  Because of the small amount of taurine in 
this product, we do not anticipate any risks to you due to this ingredient.  
 
Di-arginine malate.  The supplement contains 2242 mg of di-arginine malate, a form of the 
amino acid arginine. Potential side effects include low blood pressure and changes in various 
chemicals and electrolytes in the blood. Examples include high potassium, high chloride, low 
sodium, low phosphate, high blood urea nitrogen, and high creatinine levels.  
  
Creatine monohydrate.  The supplement contains 2750 mg of creatine monohydrate, a 
substance that is produced naturally in the body and stored in the musculature of animals to 
contribute to the production of energy. Doses of creatine used to improve training intensity and 
recovery range from 1000 to 24,000 mg per day. Large doses of creatine may cause 
dehydration and gastrointestinal distress.  However, because the combined dose of creatine 
monohydrate and di-creatine malate is at the lower end of the typical creatine dose, few side 
effects are anticipated. 
 
Betaine anhydrous.  The supplement contains 1000 mg of betaine which is associated with 
increased creatine consumption in animals.  Previous studies using higher doses of betaine did 
not report side effects.   
 
Di-creatine malate.  This supplement contains 125 mg of di-creatine malate, a form of creatine 
that is bound to malic acid which is also involved in energy production.  As previously 
mentioned large doses of creatine may cause dehydration and gastrointestinal distress. 
However, because the combined dose of creatine monohydrate and di-creatine malate is at the 
lower end of the typical creatine dose, few side effects are anticipated. 
 
Picamilon.  The supplement contains 50 mg of picamilon, a combination of niacin with γ-
Aminobutyric acid (GABA), an inhibitory neurotransmitter in the central nervous system.  
Niacin acts as a vasodilator, allowing for relaxation of the smooth muscle that surrounds the 
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vasculature.  Because of the small amount of picamilon in this product we do not anticipate any 
risks to you due to this ingredient .    
 
Beta-Alanine.  This supplement contains 750 mg of beta-alanine, a naturally occuring amino 
acid derivative.  Beta-alanine has been shown to decrease fatigue and increase work production 
in humans.  No side effects have been reported for beta alanine doses of 800 mg per day. 
 
N-Acetyl-L-Glutamine.  This supplement contains 500 mg of N-Acetyl-L-Glutamine.  L-
glutamine has been shown to neutralize cortisol, a hormone that is released during high 
intensity exercise.  This could allow for more efficient muscle growth as well as aid in the 
exercise recovery process.  Glutamine supplementation doses have ranged from 500 to over 
20,000 mg per day.  Due to the small amount of this ingredient in the supplement, no side 
effects are anticipated due to this ingredient. 
 
L-Histidine.  This supplement contains 125 mg of L-histidine.  It has been suggested that this 
amino acid is essential to the growth and repair of tissue.  Typical supplemental doses of L-
histidine range from 1,000 to 5,000 mg per day. Due to the small amount of this ingredient in 
the supplement, no side effects are anticipated due to this ingredient. 
 
Vitamin A.  The experimental supplement contains 4600 IU of Vitamin A. While the amount of 
Vitamin A in this supplement is higher than the RDA (3,000 IU) it is also lower than the upper 
intake level (10,000 IU) as well as the levels shown to cause acute or chronic toxicity (25,000 
IU/kg).  However, individuals with renal problems will not be included in this study as a 
precaution as high doses of Vitamin A place a large stress on the kidneys. 
 
Vitamin E.  The experimental supplement contains 8 IU of Vitamin E.  The recommended daily 
allowance (RDA) of this vitamin is 22.4 IU for males over the age of fourteen.  Because of the 
small amount of Vitamin E in this product we do not anticipate any risks to you due to this 
ingredient. 
 
5)  Exercise Testing and Training - During the strength testing sessions test there is a risk 
potential even though no health problems exist.  The risk and discomforts that are associated 
with this type of test include muscle fatigue, lightheadedness, chest discomfort, and very rarely 
death.  The potential for death during or immediately following the test (or any vigorous 
exercise) is approximately 0.5 per 10,000 tests, according to the American College of Sports 
Medicine.  Following these tests however you will experience muscle soreness due to the 
eccentric component of the resistance exercise.  This soreness generally referred to as delayed 
on-set muscle soreness as it is most likely to occur in the days following the exercise bout.  All 
exercise training will be prescribed relative to each subject and the principles of proper exercise 
progression and overload will be applied so as to reduce the risk of injury to the subject.  
Laboratory personnel will stay in contact with you after a testing/training session to ensure that 
you are comfortable.  You will be given a 24 hr contact number for the Applied Physiology 
Laboratory personnel to convey any type of unusual discomfort. 
 
In all of these procedures, care will be taken to employ ―universal precautions‖ for the handling 
of blood and infectious materials to ensure your safety. 
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FOLLOW UP CARE 
Following the procedure you will be provided with a biopsy care sheet, extra bandages and 
contact information for Philip Gallagher, Ph.D. After 24-hrs you must report back to the testing 
coordinator to check the wound.  At this time the bandage will be removed and properly 
disposed of and a new sterile dressing placed over the wound. You will again be asked to report 
to the test coordinator after 3-days and be contacted via phone one week after the biopsy or 
whenever necessary to ensure normal recovery.  The biopsy procedure often results in a small 
fine scar at the site of the incision, however, all care post-treatment will aid in reducing the 
potential for scarring.  All care will be taken to aid in the healing of the wound. The entire biopsy 
procedure will be performed under sterile conditions. All testing staff and associated personnel 
will be trained in first aid and will be familiar with emergency procedures.   
 
There have been no other major complications reported in the scientific literature as a result of 
taking small tissue samples from the skeletal muscle using the percutaneous needle biopsy 
technique described above. This procedure has been performed on numerous subjects by 
qualified personnel in many institutions worldwide with only slight discomfort being reported. 
During the muscle biopsy it is common to feel a strong cramping sensation in the muscle while 
the biopsy is being performed. However, muscle function is not impaired. In fact, subjects have 
been reported to continue participation in sporting events immediately following a muscle 
biopsy. It is common for subjects to experience mild soreness, moderate pain and bruising near 
the biopsy site, similar to a ―Charlie-horse‖ the day after the procedure. In order to allow the 
incisions to heal properly and minimize the risk of infection, you should not get the biopsy site 
wet for 24-hours and avoid prolonged exposure to water for 4-days. Daily showers are 
acceptable (after the first 24-hours), but baths, swimming, sauna‘s etc. should be avoided for 4-
days following the biopsy procedure. 
 
BENEFITS 
Over the course of this study you will receive information concerning your current body 
composition and fitness level as well as a personal exercise prescription.  You will also have 
trained staff monitoring your exercise sessions and tracking your progress through the program. 
You will also gain an increased understanding of resistance training and program design. A copy 
of all personal data from the tests will be provided to you and your data will be completely 
explained to you by a member of the investigation team.   
 
The results of this investigation will provide a greater knowledge of the influence of exercise 
training and use of this supplement on body composition, muscular strength and power, as well 
as blood and muscle markers of skeletal muscle growth (hypertrophy) and the inflammatory 
profile.  These findings will not only have implications on those healthy individuals that are 
trying to gain muscle mass and lose body fat but also those whose focus is to improve muscular 
strength and power. 
 
PAYMENT TO SUBJECTS 
You will receive a $200 honorarium for your participation in this nine week study.  Although not 
anticipated, if you need to discontinue the study due to an adverse event associated with the 
study, you will receive compensation.   In the event that you do not complete the entire nine 
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week study, the following payment plan has been devised:  completion of ¼ of the study will 
result in a payment of $25; completion of ½ of the study will result in payment of $50; 
completion of over ½ of the study will result in full payment.  Investigators will ask for your 
social security number in order to comply with federal and state tax and accounting regulations. 
 
COMPENSATION FOR INJURY 
The following information is provided in accordance with HEW regulations: ―In the event of 
injury, the Kansas Tort Claims Act provides for compensation if it can be demonstrated that the 
injury was caused by the negligent or wrongful act or omission of a state employee acting within 
the scope of his/her employment.‖ 
 
IN CASE OF EMERGENCY CONTACT PROCEDURE 
In the event of a research related injury or adverse reaction, please contact Philip Gallagher, 
Ph.D. at 785-864-0772 (office) or 785-550-6300 (cell), or the Applied Physiology Laboratory at 
785-864-0773. 
 
EMERGENCY CARE AND COMPENSATION IN CASE OF INJURY 
In the unlikely event that any injury or illness occurs as a result of this research, the University of 
Kansas, their officers, agents, and employees, do not automatically provide reimbursement for 
medical care or other compensation.  In cases of emergency, consistent with the Kansas Tort 
Claims Act, you would be responsible for payment of expenses related to treatments or 
associated with such complications except in a case where neglect can eventually be proven.  
You have been informed that payment for treatment of any injury or illness must be provided by 
you or your third-party payer, such as a health insurer.  If any injury or illness occurs in the 
course of research, or for more information, you will notify the investigator in charge. 
 
INFORMATION TO BE COLLECTED 
To perform this study, researchers will collect information about you. This information will be 
obtained from the health history and physical activity questionnaires, muscle biopsy, and muscle 
function evaluation. Your name will not be associated in any way with the information or tissue 
collected from you or with the research findings from this study. The researchers will use a study 
identification number or initials in place of your name.  Any data stored electronically will be 
stored on a password protected laboratory computer (not a laptop).  Any paperwork associated 
with you will be stored in a locked file cabinet secured in the Applied Physiology Laboratory.  
All tissue collected will be stored securely in the Applied Physiology Laboratory.  All tissue 
collected will be used to analyze markers of inflammation and protein synthesis. 
 
Some persons or groups that receive your information may not be required to comply with the 
Health Insurance Portability and Accountability Act‘s privacy regulations, and your information 
may lose this federal protection if those persons or groups disclose it. The researchers will not 
share information about you with anyone outside of the Applied Physiology Laboratory 
personnel unless required by law or unless you give written permission. 
 
Permission granted on this date to use and disclose your information remains in effect 
indefinitely. By signing this form you give permission for the use and disclosure of your 
information for the purposes of this study at any time in the future. 
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REFUSAL TO SIGN CONSENT AND AUTHORIZATION 
You are not required to sign this Consent and Authorization form and you may refuse to do so 
without affecting your right to any services you are receiving or may receive from the University 
of Kansas or to participate in any programs or events of the University of Kansas. However, if 
you refuse to sign, you cannot participate in this study. 
 
CANCELLING THIS CONSENT AND AUTHORIZATION 
You may withdraw your consent to participate in this study at any time. You also have the right 
to cancel your permission to use and disclose information collected about you, in writing, at any 
time, by sending your written request to: Philip Gallagher, Ph.D., University of Kansas, 1301 
Sunnyside Avenue, Robinson Center Room 101DJ, Lawrence, Kansas 66045. If you cancel 
permission to use your information, the researchers will stop collecting additional information 
about you. However, the research team may use and disclose information that was gathered 
before they received your cancellation, as described above. 
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PARTICIPANT CERTIFICATION 
I have read this Consent and Authorization form. I have had the opportunity to ask, and I have 
received answers to, any questions I had regarding the study and the use and disclosure of 
information about me for the study. I understand that if I have any additional questions about this 
study I may call Prof. Philip Gallagher (785-864-0772) or e-mail: philku@ku.edu, Becky 
Kudrna, kudrna@ku.edu or Nicole Moodie nicolejg@ku.edu. I understand that if I have any 
additional questions about my rights as a research participant, I may call 785-864-7429 or write 
the Human Subjects Committee Lawrence Campus (HSCL), University of Kansas, 2385 Irving 
Hill Road, Lawrence, Kansas 66045-7563, email mdenning@ku.edu. 
 
I agree to take part in this study titled ‗Effects of Resistance Exercise and a Pre-Workout Dietary 
Supplement on Physiological Adaptations‘ as a research participant. I further agree to the uses 
and disclosures of my information as described above. By my signature I affirm that I am at least 
18 years old and that I have received a copy of this Consent and Authorization form.  
 
___________________________________    ___________________________________ 
Print Subject‘s Name          Signature of subject 
 
__________ 
Date 
 
________________________________    ___________________________________ 
Print Name of Person         Signature of Person Obtaining Consent 
Obtaining Consent 
 
_________ 
Date 
 
_________________________________    ___________________________________ 
Print Name of Witness       Signature of Witness 
 
__________ 
Date 
 
RESEARCHER CONTACT INFORMATION 
 
Philip Gallagher   Becky Kudrna or Nicole Moodie 
Principle Investigator   Applied Physiology Lab 
Applied Physiology Lab  161D Robinson Hall 
101DJ Robinson Hall   University of Kansas 
University of Kansas   Lawrence, KS 66045  
Lawrence, KS 66045   785-864-0773 
785-864-0772     
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APPLIED PHYSIOLOGY LABORATORY 
UNIVERSITY OF KANSAS 
 
MEDICAL HISTORY FORM 
 
NAME:   DATE:  
 
AGE:   HEIGHT:   WEIGHT:   
 
A. Have you ever experienced any of the following conditions or procedures? 
 
1. Myocardial Infarction YES NO 
2. Angiography YES NO 
3. Coronary Surgery YES NO 
4. Chest Discomfort YES NO 
5. Hypertension (high blood pressure) YES NO\ 
6. Hypotension (low blood pressure)  YES NO 
 Systolic ≤ 100mmHg or Diastolic ≤ 60mmHg 
7. Shortness of breath upon light exertion YES NO 
8. Dizziness upon light exertion YES NO 
9. Pulmonary disease YES NO 
10. Heart palpitation YES NO 
11. Heart murmur YES NO 
12. Diabetes YES NO 
 If ―YES‖, Type I or Type II 
13. Extremity discomfort YES NO 
14. Claudication (circulation problems cause leg pain) YES NO 
15. Peptic Ulcers (stomach ulcer) YES NO 
16. Kidney problems YES NO 
17. Metal implants (including pins) YES NO 
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18. Seizures YES NO 
19. Have you been told by a doctor that is it not safe or appropriate 
 to exercise?   YES NO 
 
20. Does anyone in your family have a history of cardiovascular disease? YES
 NO 
 If ―YES‖, who?    
 
21. Do you smoke?  YES
 NO 
 
22. Are you currently using any anti-asthmatic medications?  YES
 NO 
 
23. Are you currently using any anti-hypertensive medications?  YES
 NO 
24. Are you currently taking any anti-inflammatory medications?  YES
 NO 
25. Are you currently taking any blood thinners (i.e.: coumadin, aspirin)? YES
 NO 
26. Are you currently taking any anti-seizure or anti-anxiety medication? YES
 NO 
27. Are you currently taking an MAOI (monoamine oxidase inhibitors)?  YES
 NO 
Common MAOIs include Phenelzine (Nardil), Tranylcypromine (Parnate), Isocarboxazid 
(Marplan), Moclobemide (Aurorix, Manerix, Moclodura), Selegiline (Selegiline, Eldepryl, 
Emsam), Nialamide, Iproniazid (Marsilid, Iporzid, Ipronid, Rivivol, Propilniazida), 
Iproclozide, and Toloxatone 
 
28. Are you currently taking any other kind of medication?  YES
 NO 
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i. If ―YES‖, please list below: 
__________________________________ 
__________________________________ 
           __________________________________ 
 
29. Are you currently taking any vitamin, mineral, or performance enhancing supplements? 
Please list them, with the dosage. 
__________________________________ 
__________________________________ 
__________________________________ 
30. Are you allergic local anesthetics (such as Novocain or lidocaine)? YES NO 
31. Are you allergic to iodine (Betadine, tincture of Iodine)? YES NO 
32. Are you allergic to Band-Aids or any other adhesive? YES NO 
33. Have you ever been treated for a heat related illness  
(heat exhaustion, heat stroke)? YES NO 
 
34. Do you have any food allergies? YES NO 
 
35. Are you allergic to any of the following?  
(If you are unsure what the ingredient is, please ask for more information and you can also 
refer to ingredient explanations in the consent form) 
 
      Natural Food flavaorings (corn syrup solids, modified food starch, medium chain                   
                triglycerides, talin, or di-alpha tocopherol) YES NO 
      Silica  YES NO 
      The Artificial Sweetener Sucralose  YES NO 
      Citric Acid  YES NO 
      Natural  Food Colors (beta-carotein) YES  NO 
      Polydextrin YES NO 
      Mannitol YES NO 
      Caffeine YES NO 
      L-Tyrosine YES NO 
      L-Citrulline-di-malate YES NO 
      Arginine Alpha-ketogluterate YES NO 
      Taurine YES NO 
      Di-arginine malate YES NO 
      Creatine monohydrate YES NO 
      Betaine anhydrous YES NO 
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      Di-creatine malate YES NO 
      Picamilon YES NO 
      Beta-Alanine YES NO 
      N-Acetyl-L-Glutamine YES NO 
      L-Histidine YES NO 
      Vitamin A YES NO 
      Vitamin E YES  NO 
     Any other Artificial Food Colors (such as yellow 5)  YES NO 
     Any artificial food flavorings YES NO 
   
                     
  
36. What is your current Cholesterol level? (If known)   
 
37.What is your current Blood-Pressure? (must be measured by APL staff) 
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Biopsy Screening Questionnaire 
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Department of Health, Sport and Exercise Sciences 
Applied Physiology Laboratory 
Muscle Biopsy Screening Form 
 
To help us ensure your safety and wellbeing, please answer the following questions honestly. 
 
1. Have you ever had an adverse or allergic reaction to a local numbing agent (e.g. during 
dental procedures)? 
Yes  No 
 
2. Are you allergic to iodine based skin cleansers (i.e. Betadine, tincture of Iodine, etc)? 
Yes  No 
 
3. Are you allergic to Band-Aids or any similar adhesive dressings? 
       Yes  No 
 
4. Do you have a tendency towards easy bleeding or bruising (e.g. with minor cuts or 
shaving)? 
Yes  No 
 
5. Please list any medications that you are taking including. Aspirin, Coumadin, Anti-
inflammatories, Plavix, etc. 
 
 
 
 
 
 
 
6. Have you ever had excessive scarring from a cut or a scrape? 
Yes  No 
 
7. Have you ever fainted or do you have a tendency to faint when undergoing or watching 
medical procedures? 
Yes  No 
 
8. Will you seek medical attention if you have any concerns about the biopsy site including: 
excessive redness, swelling, infection, pain or stiffness of the leg? 
Yes  No 
 
9. Are you willing to visit the Applied Physiology Lab to comply with the follow-up care 
and assessment of the biopsy site? 
Yes  No 
 
 
104 
 
In the unlikely event that any injury or illness occurs as a result of this research, the University of 
Kansas, their officers, agents, and employees, do not automatically provide reimbursement for 
medical care or other compensation.  In cases of emergency, consistent with the Kansas Tort 
Claims Act, you would be responsible for payment of expenses related to treatments or 
associated with such complications except in a case where neglect can eventually be proven.  
You have been informed that payment for treatment of any injury or illness must be provided by 
your or your third-party payer, such as my health insurer.  If any injury or illness occurs in the 
course of research, or for more information, you will notify the investigator in charge. 
 
 
Subject Name (print):____________________________________________________________ 
 
Subject Signature:_______________________________________________________________ 
 
Date: __________________ 
 
Witness Signature:______________________________________________________________ 
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Physical Activity Questionnaire 
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Exercise Training History Questionnaire 
1. At what age did you start resistance training?  
 
2. Since then how regular, have you been with resistance training?  
 
a. Have / do you take breaks from resistance training longer than 2 weeks? How frequently? 
 
b. Have / do you take breaks from resistance training longer than 1 month? How frequently? 
 
c. Have / do you take breaks from resistance training longer than 3 months? How frequently? 
 
d. When, and for what reasons did you take such breaks?  
 
3. When you first became serious about resistance training what was you main reason?  
a. Sport(s):   List_____________________level of competition_________________ 
b. Fitness     
c. Competitive Lifting:   (powerlifting, olympic lifting, strongman, other) 
d. Rehabilitation 
e. Other:  Explain____________________________________________________ 
 
4. What is your reason for resistance training now?  
a. Sport(s):   List_____________________level of competition_________________ 
b. Fitness     
c. Competitive Lifting:   (powerlifting, olympic lifting, body building, strongman, 
other) 
d. Rehabilitation 
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e. Other:  Explain____________________________________________________ 
 
5. In the last 6 months, How many times per week have you typically resistance trained? 
(Include multiple sessions per day separately). 
a. Time per week upper body  ____________ 
b. Times per week lower body  ____________ 
c. Total times per week    _____________ 
 
6. In the last 6 months, How many weeks have you participated in resistance training one time 
or LESS per week? (include vacations, breaks, and schedule conflicts). 
 
7. In the last 6 months, How many weeks have you participated in resistance training three 
times or MORE per week? (Include multiple sessions per day separately). 
8. When you lift, do you usually work at a percentage of your known maximum or by what 
other  method do you choose a weight for each lift? 
 
9. Estimate your 1RM Max, or provide how much you think that you could lift for a given 
number of repetitions. 
LIFT I have done 
this exercise 
in the last 6 
months 
Predicted Maximum 
Weight 
Weight I 
usually use 
Number of 
Repetitions I usually 
do 
BENCH PRESS Yes     No    
INCLINE BENCH  Yes     No    
PARRALLEL SQUAT Yes     No    
FULL SQUAT  
(below parallel) 
Yes     No    
DEADLIFT Yes     No    
STANDING PRESS Yes     No    
LUNGES (WITH BARBELL) Yes     No    
LEG EXTENSION Yes     No    
LEG CURLS Yes     No    
BICEP CURLS Yes     No    
PULL-UPS Yes     No    
DIPS Yes     No    
 
108 
 
10. Create in the space below a representation of your TYPICAL exercise session in the last 6 
months.  If you perform lower and upper body movements on separate days list each day 
separately below.  
 
EXERCISE   SETS AND REPS   POUNDAGE’S 
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11. How many times per week do you participate in stretching? _____________ 
12. How many years/months have you been performing cardiovascular exercise?  
 
13. Since you began have / do you take breaks from cardiovascular training longer than 2 
weeks? How frequently? 
 
14. Since you began, have / do you take breaks from cardiovascular training longer than 1 
month? How frequently? 
 
15. Have / do you take breaks from cardiovascular  training longer than 3 months? How 
frequently? 
 
16. When, and for what reasons did you take such breaks?  
 
17. What is your Current reason for participating in cardiovascular training now?  
a. Sport(s):   List_____________________level of competition_________________ 
b. Health / Fitness: Explain ____________________________________________    
c. Rehabilitation 
d. Other:  Explain____________________________________________________ 
 
 
18. In the last 6 months, How many times per week have you typically participated in 
cardiovascular exercise? (Include multiple sessions per day separately).  
 
19. In the last 6 months, How many weeks have you participated in cardiovascular exercise one 
time or LESS per week? (include vacations, breaks, and schedule conflicts). 
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20. In the last 6 months, How many weeks have you participated in cardiovascular exercise 
training three times or MORE per week? (Include multiple sessions per day separately). 
 
21. When you run, row, swim, etc, do you usually work at a percentage of your Heart Rate 
Maximum, aim for a particular time goal, or by what other  method do you choose your 
intensity? 
 
 
22. Create a TYPICAL weeks exercise log of cardiovascular exercises below. Use only the last 
six months as a guide. Include type of exercise, the duration, and the intensity or pace at which 
you perform this task.  If you monitor your HR please include that information as well. Provide 
as much detail as possible use additional paper if needed.  
 TYPE OF 
EXERCISE 
DURATION PACE INTENSITY 
MONDAY     
TUESDAY     
WEDNESDAY     
THURSDAY     
FRIDAY     
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SATURDAY     
SUNDAY     
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Caffeine Intake Questionnaire 
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Caffeine Intake and Tolerance Questionnaire 
1. How many cups of caffeinated coffee, tea, soda, and energy drinks (red bull, full throttle 
etc. ) do you consume on a typical weekday?  
 
 
2. How many cups of caffeinated coffee, tea, soda, and energy drinks (red bull, full throttle 
etc. ) do you consume on a typical weekend day?  
 
 
3. Do you consider yourself addicted to caffeine? YES  NO 
 
 
4. Do you ever get headaches or feel unwell because you  
did not get caffeine or coffee at your usual time?   YES  NO 
 
 
5. Do you feel that you need a caffeinated beverage  
to wake up in the morning?   YES  NO 
 
 
6. If you take part in this study will you be able 
 to reduce or eliminate caffeine from your diet?  YES  NO 
 
 
7. Have you ever had too much caffeine such that 
 it caused negative side effects like rapid heart rate, 
 anxiety, rapid breathing, or jitters?    YES  NO 
 
a. IF yes, approximately how much caffeine (or how much soda, coffee, tea) did you 
consume?  (you will find caffeine amounts for common foods on the next page) 
 
_________________________________________________________________ 
 
__________________________________________________________________ 
 
b. If NO, What is the most caffeine you have ever consumed in a 3 hour period? ( or 
how much soda, coffee, tea) did you consume? (you will find caffeine amounts 
for common foods on the next page) 
 
_________________________________________________________________ 
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Caffeine Content of Popular Drinks 
12-ounce beverage milligrams 
Red Bull (8.2 oz)  80.0 
Jolt  71.2 
Pepsi One 55.5 
Mountain Dew / Diet Mountain Dew / Code Red 55.0 
Mellow Yellow / Surge 52.8 
Tab / RC Cola / Diet RC 46.8 
Diet Coke  45.6 
Dr. Pepper/ Diet Dr. Pepper / Mr. Pibb 41.0 
Pepsi-Cola / Diet Pepsi / Wild Cherry Pepsi 37.5 
Coca-Cola Classic  34.0 
Snapple Flavored Teas (Reg. or Diet)  31.5 
Nestea Sweet Iced Tea 26.5 
Nestea Unsweetened Iced Tea 26.0 
Lipton Diet Green Tea with Citrus (16.9 oz) 23.0 
Barq's Root Beer  23.0 
Lipton Brisk, All Varieties 9 
Diet Rite Cola 0 
Sprite /7-Up / Slice / Sierra Mist / Fresca 0 
Mug / Diet Barq's Root Beer /A&W Root Beer 0 
Sundrop Orange / Minute Maid Orange 0 
8-ounce Beverage milligrams 
Coffee, Drip  115-175  
Coffee, Brewed  80-135 
Coffee, Espresso (2 ounces) 100 
Tea, iced  47 
Tea, brewed, imported brands (avg.) 50 
Tea, instant  30 
Tea, green  15 
Hot cocoa 14 
Coffee, Decaf,  3-4 
 
Dark Chocolate:  10-30 mg per ounce          Milk Chocolate:  5-10mg / oz 
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Supplement Side Effects Questionnaire
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Effects of Resistance Exercise and a Pre-Workout Dietary Supplement on 
Physiological Adaptations 
Side Effects Questionnaire 
 
Have you experienced any of the following since your last training session? 
 
 Dizziness or light headedness     YES NO   
 Nervousness or ‗jitters‘     YES NO 
 Indigestion       YES NO 
 Stomach discomfort      YES NO 
 Other: (please explain)     
 
If so, when did this occur? 
 
If you circled ―yes‖ for any of the above, answer the next question according to the following 
scale: 
 1 = some, but no influence on normal functioning 
 2 = moderate, but minor influence on normal functioning 
 3 = severe; inability to maintain normal functioning 
 
How would you rate the supplement side effects that you have experienced since your last 
training session? 
  
     1  2  3 
 
Have you experienced any of the following since you ingested the supplement/placebo 
drink today? 
  
 Dizziness or light headedness     YES NO  
 Nervousness or ‗jitters‘     YES NO 
 Indigestion       YES NO  
 Stomach discomfort      YES NO 
 Other: (please explain)     
 
If so, when did this occur? Circle all that apply. 
 Immediately (prior to workout) 
 During my workout 
 Immediately following my workout 
 
If you circled ―yes‖ for any of the above, answer the next question according to the following 
scale: 
 1 = some, but no influence on normal functioning 
 2 = moderate, but minor influence on normal functioning 
 3 = severe, inability to maintain normal functioning 
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How would you rate the supplement side effects that you have experienced since your last 
training session? 
  
     1  2  3 
 
Are you experiencing any joint or muscle pain that has stemmed from the exercise program? 
YES NO 
 
If so, please explain. 
 
Wednesday Blood Pressure Reading:  ____________ 
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Whole Muscle Data 
 
 
Subject Group Height Weight Weight(kg) Body Fat  LBM (kg) 
1 2 69.3 180.5 82.04 20.8 62.04 
2 2 70.3 169.6 77.10 18.0 59.87 
3 2 68.2 145.4 66.09 14.5 54.04 
4 2 76.0 175.9 79.97 12.0 67.31 
5 1 72.6 171.5 77.95 16.1 65.25 
6 1 68.3 174.5 79.34 21.1 59.54 
7 1 75.0 163.9 74.50 10.6 63.35 
8 1 70.4 187.8 85.36 20.6 64.51 
9 1 70.3 164.8 74.93 13.4 62.20 
10 1 71.7 161.1 73.22   8.4 63.82 
11 1 71.4 177.7 80.79 23.0 59.24 
12 1 69.8 204.1 92.77 30.7 61.35 
13 1 71.6 173.0 78.63 11.2 66.55 
14 1 70.0 163.8 74.45 11.7 62.65 
15 1 70.6 143.1 65.06 12.9 53.87 
16 2 70.7 155.7 70.77  8.9 61.39 
17 1 69.7 150.2 68.27 18.7 52.85 
18 2 69.7 165.1 75.05   7.9 66.23 
19 2 77.0 192.2 87.36 20.0 65.69 
20 1 72.1 190.6 86.63 20.3 66.07 
21 2 68.7 163.1 74.15 18.8 57.42 
22 1 70.6 173.1 78.70 16.4 62.54 
23 2 66.5 200.7 91.22 29.8 61.12 
24 2 74.0 165.3 75.15 11.9 62.40 
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Whole Muscle Data 
 
 
Subject Group (#) 
Pre Squat 
Max (kg) 
Pre Bench 
Max (kg) 
1 2 245 111.36 225 102.27 
2 2 235 106.81 160 72.72 
3 2 165 75.00 135 61.36 
4 2 225 102.27 155 70.45 
5 1 225 102.27 165 75.00 
6 1 260 118.18 195 88.63 
7 1 205 93.18 160 72.72 
8 1 235 106.81 165 75.00 
9 1 235 106.81 180 81.81 
10 1 240 109.09 175 79.54 
11 1 215 97.72 165 75.00 
12 1 365 165.90 185 84.09 
13 1 280 127.27 175 79.54 
14 1 295 134.09 215 97.72 
15 1 185 84.09 135 61.36 
16 2 270 122.72 230 104.54 
17 1 205 93.18 135 61.36 
18 2 335 152.27 205 93.18 
19 2 195 88.63 145 65.90 
20 1 295 134.09 215 97.72 
21 2 245 111.36 195 88.63 
22 1 225 102.27 185 84.09 
23 2 265 120.45 175 79.54 
24 2 185 84.09 145 65.90 
 
 
 
 
       
        
        
123 
 
 Whole Muscle Data 
 
 
Subject Group (#) Pre Leg Ex Max (kg) 
Pre Leg Curl 
Max (kg) 
1 2 230 104.54 190 86.36 
2 2 170 77.27 180 81.81 
3 2 180 81.81 140 63.63 
4 2 190 86.36 170 77.27 
5 1 120 54.54 210 95.45 
6 1 200 90.90 170 77.27 
7 1 200 90.90 170 77.27 
8 1 220 100.00 180 81.81 
9 1 220 100.00 160 72.72 
10 1 200 90.90 170 77.27 
11 1 190 86.36 180 81.81 
12 1 175 79.54 170 77.27 
13 1 220 100.00 200 90.90 
14 1 245 111.36 160 72.72 
15 1 130 59.09 90 40.90 
16 2 190 86.36 170 77.27 
17 1 160 72.72 150 68.18 
18 2 180 81.81 150 68.18 
19 2 230 104.54 190 86.36 
20 1 245 111.36 200 90.90 
21 2 200 90.90 150 68.18 
22 1 220 100.00 170 77.27 
23 2 170 77.27 120 54.54 
24 2 190 86.36 170 77.27 
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Whole Muscle Data 
 
Subject Group (#) 
Pre Lat 
Pulldown Max (kg) 
Pre Deadlift 
Max (kg) 
1 2 230 104.54 355 161.36 
2 2 190 86.36 275 125.00 
3 2 170 77.27 215 97.72 
4 2 160 72.72 245 111.36 
5 1 190 86.36 305 138.63 
6 1 200 90.90 295 134.09 
7 1 190 86.36 205 93.18 
8 1 140 63.63 245 111.36 
9 1 230 104.54 255 115.90 
10 1 190 86.36 275 125.00 
11 1 200 90.90 155 70.45 
12 1 200 90.90 355 161.36 
13 1 200 90.90 345 156.81 
14 1 220 100.00 365 165.90 
15 1 115 52.27 225 102.27 
16 2 220 100.00 315 143.18 
17 1 160 72.72 205 93.18 
18 2 225 102.27 305 138.63 
19 2 190 86.36 285 129.54 
20 1 210 95.45 365 165.90 
21 2 180 81.81 275 125.00 
22 1 200 90.90 235 106.81 
23 2 200 90.90 275 125.00 
24 2 180 81.81 235 106.81 
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Whole Muscle Data 
 
Subject Group (#) Pre Incline Max (kg) Pre Curls Max (kg) 
1 2 185 84.09 75 34.09 
2 2 130 59.09 80 36.36 
3 2 125 56.81 45 20.45 
4 2 145 65.90 60 27.27 
5 1 155 70.45 75 34.09 
6 1 185 84.09 80 36.36 
7 1 145 65.90 65 29.54 
8 1 145 65.90 50 22.72 
9 1 165 75.00 80 36.36 
10 1 145 65.90 55 25.00 
11 1 225 102.27 65 29.54 
12 1 180 81.81 80 36.36 
13 1 165 75.00 85 38.63 
14 1 190 86.36 105 47.72 
15 1 115 52.27 55 25.00 
16 2 175 79.54 90 40.90 
17 1 130 59.09 50 22.72 
18 2 195 88.63 95 43.18 
19 2 135 61.36 80 36.36 
20 1 205 93.18 80 36.36 
21 2 175 79.54 80 36.36 
22 1 165 75.00 75 34.09 
23 2 175 79.54 80 36.36 
24 2 150 68.18 75 34.09 
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Whole Muscle Data 
 
Subject Group (#) Post Wt (kg) Post % Fat Post Lean Mass Post LBM (kg) 
1 2 84.00 19.2 142.73 64.88 
2 2 76.59 16.7 133.39 60.63 
3 2 68.36 16.7 119.62 54.37 
4 2 81.77 10.7 149.57 67.98 
5 1 79.97 14.6 142.86 64.94 
6 1 82.95 23.4 133.32 60.60 
7 1 76.63 10.3 144.98 65.90 
8 1 87.22 22.6 140.91 64.05 
9 1 75.70 13.3 138.25 62.84 
10 1 77.29 7.8 150.17 68.26 
11 1 81.88 23 131.91 59.96 
12 1 95.45 29.7 141.08 64.12 
13 1 77.47 9.9 146.07 66.39 
14 1 75.72 12.2 139.35 63.34 
15 1 64.81 10.7 121.18 55.08 
16 2 71.34 8.9 136.08 61.85 
17 1 70.47 16.8 123.42 56.10 
18 2 75.31 8.3 145.08 65.94 
19 2 91.25 19.3 151.39 68.81 
20 1 87.47 18.9 149.43 67.92 
21 2 77.56 22.3 126.37 57.44 
22 1 80.90 14.5 145.25 66.02 
23 2 96.88 29.3 143.90 65.40 
24 2 73.84 9.4 139.35 63.34 
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Whole Muscle Data 
 
Subject Group (#) 
Post Squat 
Max (kg) 
Post Bench 
Max (kg) 
1 2 295 134.09 255 115.90 
2 2 280 127.27 165 75.00 
3 2 235 106.81 150 68.18 
4 2 275 125.00 175 79.54 
5 1 300 136.36 190 86.36 
6 1 335 152.27 225 102.27 
7 1 250 113.63 185 84.09 
8 1 330 150.00 190 86.36 
9 1 315 143.18 215 97.72 
10 1 390 177.27 205 93.18 
11 1 275 125.00 205 93.18 
12 1 420 190.90 220 100.00 
13 1 375 170.45 190 86.36 
14 1 335 152.27 250 113.63 
15 1 250 113.63 145 65.90 
16 2 300 136.36 240 109.09 
17 1 265 120.45 165 75.00 
18 2 370 168.18 220 100.00 
19 2 275 125.00 160 72.72 
20 1 340 154.54 260 118.18 
21 2 305 138.63 210 95.45 
22 1 315 143.18 225 102.27 
23 2 375 170.45 225 102.27 
24 2 265 120.45 170 77.27 
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Whole Muscle Data 
 
Subject Group (#) Post Leg Ex Max (kg) 
Post Leg Curl 
Max (kg) 
1 2 245 111.36 210   95.45 
2 2 215 97.72 180   81.81 
3 2 220 100.00 170   77.27 
4 2 250 113.63 185   84.09 
5 1 260 118.18 220 100.00 
6 1 245 111.36 180   81.81 
7 1 265 120.45 205   93.18 
8 1 290 131.81 200   90.90 
9 1 260 118.18 170   77.27 
10 1 235 106.81 200   90.90 
11 1 250 113.63 210   95.45 
12 1 315 143.18 210   95.45 
13 1 260 118.18 210   95.45 
14 1 280 127.27 180   81.81 
15 1 195 88.63 170   77.27 
16 2 245 111.36 185   84.09 
17 1 245 111.36 165   75.00 
18 2 235 106.81 180   81.81 
19 2 300 136.36 220 100.00 
20 1 265 120.45 220 100.00 
21 2 275 125.00 205   93.18 
22 1 275 125.00 210   95.45 
23 2 260 118.18 180   81.81 
24 2 275 125.00 185   84.09 
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Whole Muscle Data 
 
Subject Group (#) 
Post Lat 
Pulldown Max (kg) 
Post Deadlift 
Max (kg) 
1 2 230 104.54 365 165.90 
2 2 200   90.90 N/A N/A 
3 2 180   81.81 265 120.45 
4 2 185   84.09 255 115.90 
5 1 220 100.00 365 165.90 
6 1 210   95.45 325 147.72 
7 1 200   90.90 300 136.36 
8 1 190   86.36 325 147.72 
9 1 245 111.36 310 140.90 
10 1 240 109.09 335 152.27 
11 1 215   97.72 285 129.54 
12 1 235 106.81 365 165.90 
13 1 210   95.45 350 159.09 
14 1 235 106.81 365 165.90 
15 1 145   65.90 290 131.81 
16 2 235 106.81 335 152.27 
17 1 185   84.09 265 120.45 
18 2 235 106.81 365 165.90 
19 2 220 100.00 325 147.72 
20 1 235 106.81 405 184.09 
21 2 210   95.45 330 150.00 
22 1 230 104.54 305 138.63 
23 2 235 106.81 405 184.09 
24 2 205   93.18 235 106.81 
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Whole Muscle Data 
 
Subject Group (#)    Post Incline Max (kg) Post Curls Max    (kg) 
1 2 205   93.18 90 40.90 
2 2             N/A   N/A N/A N/A 
3 2 140   63.63 75 34.09 
4 2 165   75.00 75 34.09 
5 1 170   77.27 80 36.36 
6 1 205   93.18 90 40.90 
7 1 170   77.27 80 36.36 
8 1 160   72.72 80 36.36 
9 1 185   84.09 85 38.63 
10 1 185   84.09 75 34.09 
11 1 165   75.00 80 36.36 
12 1 200   90.90 100 45.45 
13 1 175   79.54 100 45.45 
14 1 220 100.00 105 47.72 
15 1 120   54.54 70 31.81 
16 2 190   86.36 100 45.45 
17 1 155   70.45 65 29.54 
18 2 210   95.45 100 45.45 
19 2             N/A   N/A N/A N/A 
20 1 230 104.54 105 47.72 
21 2 195   88.63 90 40.90 
22 1 195   88.63 100 45.45 
23 2 205   93.18 105 47.72 
24 2 150   68.18 80 36.36 
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Protein Extraction/Concentration Data 
PRE 1 
 
      Subject          Group     Sample Size (mg)                Mean BSA 
1 2 19.4 26.6 
2 2 13.88 21.37 
3 2 16.31 23.73 
4 2 15.79 22.63 
5 1 12.4 36.42 
6 1 15.75 24.22 
7 1 17.26 28.79 
8 1 16.73 24.16 
9 1 13.78 24.18 
10 1 17.81 14.6 
11 1 13.87 19.74 
12 1 16.27 27.44 
13 1 16.8 23.07 
14 1 16.5 22.58 
15 1 13.38 25.18 
16 2 13.92 25.1 
17 1 15.41 30.69 
18 2 14.65 33.17 
19 2 20.1 31.63 
20 1 18.7 25.99 
21 2 16.08 27.68 
22 1 16.55 29.43 
23 2 15.21 20.48 
24 2 19.22 32.43 
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Protein Extraction/Concentration Data 
PRE 2 
 
      Subject          Group     Sample Size (mg)                 Mean BSA 
1 2 16.21 20.84 
2 2 14.05 20.07 
3 2 17.52 18.20 
4 2 17.73 23.10 
5 1 14.50 24.55 
6 1 17.03 19.54 
7 1 16.13 23.49 
8 1 18.90 24.57 
9 1 15.44 26.49 
10 1 20.15 23.98 
11 1 20.06 27.59 
12 1 20.33 31.15 
13 1 16.84 26.84 
14 1 16.40 28.05 
15 1 17.04 25.18 
16 2 17.49 25.12 
17 1 19.52 39.74 
18 2 16.53 25.90 
19 2 15.21 27.44 
20 1 14.62 25.64 
21 2 19.14 31.76 
22 1 19.98 22.21 
23 2 13.99 24.84 
24 2 14.77 30.67 
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Protein Extraction/Concentration Data 
POST 1 
 
      Subject         Group        Sample Size (mg)                    Mean BSA 
1 2 17.05 33.06 
2 2 16.35 27.94 
3 2 20.87 27.57 
4 2 17.89 32.98 
5 1 16.03 32.72 
6 1 12.79 27.27 
7 1 19.06 27.45 
8 1 17.17 22.33 
9 1 19.32 31.89 
10 1 15.11 20.66 
11 1 17.55 29.33 
12 1 17.83 25.52 
13 1 15.32 20 
14 1 15.66 24.23 
15 1 20.65 33.36 
16 2 16.63 30.76 
17 1 17.57 26.05 
18 2 15.57 21.83 
19 2 15.71 27.31 
20 1 16.41 30.56 
21 2 19.88 37.62 
22 1 14.5 23.14 
23 2 18.35 32.02 
24 2 15.37 25.63 
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Protein Extraction/Concentration Data 
POST 2 
 
      Subject          Group             Sample Size (mg)                         Mean BSA 
1 2 18.96 27.89 
2 2 16.7 27.35 
3 2 19.75 23.8 
4 2 18.96 33.71 
5 1 18.45 27.23 
6 1 20.66 38.33 
7 1 17.61 27.06 
8 1 17.02 25.33 
9 1 17.37 23.24 
10 1 14.82 23.02 
11 1 14.48 23.49 
12 1 18.48 33.92 
13 1 18.33 22.89 
14 1 16.31 27.42 
15 1 17.58 26.82 
16 2 19.5 25.9 
17 1 17.32 33.08 
18 2 17.92 25.88 
19 2 17.05 30.77 
20 1 16.65 27.87 
21 2 18.99 27.8 
22 1 16.56 26.23 
23 2 18.05 30.74 
24 2 17.54 34.04 
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Western Immunoblotting Densitomety Values (arbitrary units) 
 
Subject  Group Average PRE1 Average PRE2 
          1         2 18697360 30813810 
          2         2 32405688 16797921 
          3         2 7620946.667 13378720.67 
          4         2 23989664 33144001 
          5         1 11173092.33 34387213.33 
          6         1 7060534 9032679.333 
          7         1 9272912 9621170 
          8         1 10921680 9802786.333 
          9         1 15362594.67 12941473.67 
        10         1 17504065 14802852 
        11         1 17646318 20637173.33 
        12         1 18605730 19563226.67 
        13         1 27352052 22455450 
        14         1 26148096 9698803.333 
        15         1 7100025 11617289.33 
        16         2 17043891.33 15955480.67 
        17         1 60660550 19058466.67 
        18         2 33823884 18897016 
        19         2 13826782 13434446.67 
        20         1 9956805 12056146.33 
        21         2 9711920 9751560 
        22         1 8327172.667 11355557 
        23         2 20460578.67 10793979.33 
        24         2 6017496 6234972.333 
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Western Immunoblotting Densitomety Values (arbitrary units) 
 
Subject  Group Average POST1 Average POST2 
          1         2 10093835 8361418.667 
          2         2 8299383.333 5285510.667 
          3         2 16283800 9700831.333 
          4         2 8077039 10628220 
          5         1 7567199.333 6016708.667 
          6         1 4770268 5454923.667 
          7         1 3596622 4946281.333 
          8         1 4918086.667 4775516 
          9         1 7405092 9110728 
        10         1 4705536 8182230 
        11         1 3891372.667 4428390 
        12         1 3699333.333 3138294.333 
        13         1 6446258 3683189 
        14         1 4696800 6285740.333 
        15         1 5396841 5953321.333 
        16         2 4602645 10738884 
        17         1 17772506.67 12372425 
        18         2 13562985.33 11761656.67 
        19         2 7082670 5338410 
        20         1 4267121.333 5263954 
        21         2 6366822 4973696 
        22         1 6589823.333 7252674 
        23         2 2523709.667 2407310 
        24         2 14778345.67 6167304 
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ELISA Data 
 
Subject Group 
IL1α 
PRE1 
IL1α 
PRE2 
IL1β 
PRE1 
IL1β 
PRE2 
IL2   
PRE1             
IL2 
PRE2 
1         2 63123.77 35754.8 6929.235 5585.552 2038.24 2038.98 
2         2 34984.79 5783.87 33647.05 3446.618 30153.4 1941.63 
3         2 1855.35 21810.04 3603.113 32385.27 1907.42 23923 
4         2 3231.417 5024.976 33022.84 26010.34 2147.62 10390 
5         1 5814.66 5887.885 2442.382 3476.842 1745.09 1813.3 
6         1 3720.5 3483.958 15876.07 8807.283 2754.69 2360.33 
7         1 5245.962 3678.905 3184.286 2760.052 2309.25 13911.2 
8         1 3028.975 4624.296 8218.431 6317.618 1623.82 8715.85 
9         1 1257.688 1779.542 1779.542 5087.517 1257.69 1779.54 
10         1 4045.906 3675.427 2829.771 2896.575 1602.58 1465.05 
11         1 6828.188 5865.294 2877.174 2823.893 1216.11 1549.98 
12         1 5431.558 4813.864 3742.398 3932.094 1332.52 9646.4 
13         1 5287.639 5682.099 2691.183 3102.923 1673.44 1392.18 
14         1 5964.772 6949.579 5475.72 5614.073 1798.68 1957.24 
15         1 2532.407 1715.167 1715.167 7782.5 2532.41 1715.17 
16         2 5686.976 4972.769 5149.45 6152.643 17428.3 18355.9 
17         1 8424.781 6018.533 5089.406 5290.656 2637.16 1895.07 
18         2 5232.413 7521.589 2752.511 3173.693 1540.15 1420.92 
19         2 4140.963 4258.536 2887.314 3382.031 31761.8 15244.4 
20         1 5145.663 5240.125 2319.896 3450.761 14053.7 18897.7 
21         2 4625.969 5618.992 2184.794 2373.684 1707.88 1725.33 
22         1 29912.93 4167.698 32928.14 9046.318 29139.1 2437.29 
23         2 8248.238 7538.587 2652.889 3046.234 2047.53 1853.83 
24         2 8969.9 6673.975 4954.859 3515.675 2672.38 1844.91 
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ELISA Data 
 
Subject Group 
IL4  
PRE1 
IL4  
PRE2 
IL6  
PRE1 
IL6  
PRE2 
IL-8 
PRE1 
IL8 
PRE2 
1         2 7569.71875 6632.7071 31192.143 21655.306 32103.844 29219.4 
2         2 32843.92188 6101.3009 17376.164 3375.9792 42164.367 18910.4 
3         2 5993.571023 32900 2148.8586 30052.3 16161.143 41541.6 
4         2 18872.44231 17782.528 13480.656 12572.575 55161.365 35594.6 
5         1 4854.457895 4312.3611 2559.6143 3007.2935 21097.835 18594.6 
6         1 5252.016667 3733.4811 3555.375 3753.2024 15134.007 16340.4 
7         1 12363.2619 7595.7955 3224.1008 3296.0625 19315.643 8966.89 
8         1 7731.1875 7542.5625 5018.5915 7746.7104 28022.644 18975.8 
9         1 30042.33333 5019.4869 2361.9722 3640.8421 19039.722 13759.3 
10         1 4918.075569 4734.8153 2252.7917 2662.1734 13581.636 14417 
11         1 5135.169913 4600.9895 2421.5143 3587.2292 30552.25 34246.2 
12         1 4982.315789 8204.1667 2797.2569 5893.125 16766.438 12488.2 
13         1 4575.75 4930.9318 2312.1082 2627.5263 19377.805 20166.6 
14         1 3936.904762 5645.125 3428.3158 3965.5381 20421.225 19535.6 
15         1 6078.027778 5323.7944 2621.8 2691.0432 10135.977 10575.5 
16         2 7719.008373 10626.435 5492.625 5783.2566 8392.1125 8988.65 
17         1 6176.214976 4544.3333 3355.4783 3789.9391 23850.304 23185.7 
18         2 3491.258333 4634.9386 3258.0812 2995.4348 17373.072 19057.1 
19         2 6578.535897 6838.4471 4608.0625 4384.2847 7010.4405 7054.45 
20         1 6855.166667 8177.1 6061.4063 5040.6335 8617.0303 9720.84 
21         2 3726.538636 4507.8505 4722.536 2109.26 16913.791 14799.6 
22         1 33341.80707 6338.0341 14894.245 3360.5852 43984.385 20908.6 
23         2 5398.885417 4598.0909 2731.1563 2871.7895 10120.313 18843.1 
24         2 6289.741228 4647.6404 3391.1402 7495.2974 19925.11 15480.3 
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ELISA Data 
 
Subject Group 
IL10 
PRE1 
IL10 
PRE2 
IFNγ  
PRE1 
IFNγ  
PRE2   
1         2 13010.633 11985.038 10526.22321 8407.582707   
2         2 7988.486 9477.4688 33075.78125 7155.991667   
3         2 6339.6244 34604.58 7181.84375 32682.26087   
4         2 21643.571 13852.015 23804.98011 15452.69173   
5         1 6598.5675 8625.2639 5049.120773 5734.409091   
6         1 59478.222 32756.087 6003.391667 4527.857143   
7         1 7693.4708 4604.6458 5737.5625 2847.393939   
8         1 43995.75 28351.115 7030.113636 4655.402174   
9         1 7518.3048 9984.5179 5304.633152 6447.5625   
10         1 6170.4042 7544.7403 5493.666667 4983.619048   
11         1 7767.5 8279.3571 5626.998551 5174.78125   
12         1 5790.5378 6912.5852 5494.761696 3760.740489   
13         1 4770.1833 4422.5208 5004.451128 6040.1875   
14         1 9993.1591 12200.585 6076.915179 7622.704545   
15         1 21700.5 13320.658 4856.75 4742.068182   
16         2 2155.256 2250.6857 1450.461905 1712   
17         1 8995.8889 9036.4271 8903.487154 6790.47488   
18         2 8510.9688 8420.1193 4410.47619 6143.269737   
19         2 1511.0125 1861.1354 1675 1834.354167   
20         1 2124.88 3122.5518 2485.178571 2424.119048   
21         2 9468.8563 5937.939 3907.181704 4384.8   
22         1 10408.362 35627.287 31042.87054 6083.921053   
23         2 7537.3684 9617.2667 5214.742063 5483.121212   
24         2 17772.01 30196.781 6321.10462 5048.954545   
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ELISA Data 
 
Subject Group 
TNFα  
PRE1 
TNFα  
PRE2 
IL1α 
POST1 
IL1α  
POST2 
1         2 16289.938 12194.4 62687.8387 32731.89167 
2         2 38050.15 9579.798295 5626.45 6662.704861 
3         2 6043.9892 35186.77083 1679.90476 20751.24943 
4         2 49727.921 30582.0767 2875.16667 3873.277193 
5         1 9778.3708 9072.17193 4670.81667 4402.70303 
6         1 18452.767 12742.37778 4636.36508 3522.3125 
7         1 8551.4762 4327.882997 5744.57292 5138.133224 
8         1 15337.267 9146.794444 2810.95833 3210.882576 
9         1 8419.1875 7927.147727 5394.4 3631.333333 
10         1 7148.6807 8225.045139 5052.07644 8485.111111 
11         1 8526.419 7788.061265 5265.24554 4575.1 
12         1 9683.5278 6266.7 3952.50833 4429.416667 
13         1 7021.1389 7401.02381 5824.67143 4836.139394 
14         1 10362.694 10566.05 5202.57986 8964.46875 
15         1 11254.625 7741.315789 40778.0479 39448.23864 
16         2 1787.5455 2378.412879 5063.06667 6033.217949 
17         1 11645.717 9065.828571 10817.7783 5804.226316 
18         2 7889.4778 9019.246528 6059.20556 5804.226316 
19         2 1912.8148 1687.021739 10817.7783 6059.205556 
20         1 2215.4333 3066.653846 1456.4697 1605.625 
21         2 7347.9104 6086.53125 26716.153 1307.270833 
22         1 31767.903 14204.09375 1089.90805 997.394958 
23         2 6859.6667 7861.604978 1879.17017 1290.492424 
24         2 9621.3153 7351.638095 5159.13889 5739.750877 
 
 
141 
 
ELISA Data 
 
 
 
Subject Group 
IL1β  
POST1 
IL1β  
POST2 
IL2 
POST1 
IL2 
POST2 
1         2 7209.15035 9061.453557 2125.12319 1759.1417 
2         2 2436.447222 3429.40625 1257.03704 1263.8523 
3         2 2942.858553 32838.55466 1568.0625 17750.875 
4         2 17912.82955 11804.68254 1689.25 2562.5414 
5         1 1548.019608 1848.940476 1576.95833 1418.9167 
6         1 13845.80114 16998.38393 2914.125 4056.3958 
7         1 1820.454545 1879.568452 1710.91111 1797.9722 
8         1 6677.75 9788.455592 1796 2635.3346 
9         1 2184.840351 1895.198684 1603.93333 1098.9667 
10         1 2315.4375 2759.194444 1370.30667 6496.875 
11         1 2776.672222 2665.718421 1369.66667 1699.8288 
12         1 2018.3 1953.961538 1965.8625 1929.8542 
13         1 11882.01877 10296.6865 2186.81731 1838.3021 
14         1 2867.327083 5747.883152 1038.97727 1780.8956 
15         1 62935.42308 62602.00507 36142.25 46063.225 
16         2 4711.377778 8608.308333 2096.42535 4565.0468 
17         1 3333.04386 3799.383838 1738.63968 1628.6626 
18         2 3543.846726 3799.383838 1894.29412 1628.6626 
19         2 3333.04386 3543.846726 1738.63968 1894.2941 
20         1 1605.625 2771.483333 1456.4697 1605.625 
21         2 1307.270833 33654.48148 26716.153 1307.2708 
22         1 997.394958 2117.654762 1089.90805 997.39496 
23         2 1290.492424 2553.953947 1879.17017 1290.4924 
24         2 2175.209821 2046.551487 1157.4087 1065.0128 
 
 
 
 
142 
 
ELISA Data 
 
 
 
Subject Group 
IL4 
POST1 
IL4 
POST2 
IL6 
POST1 
IL6 
POST2 
1         2 8292.4688 7862.2375 47107.21875 18865.61 
2         2 4604.6439 4503.3561 2229.026316 3071.559 
3         2 4559.3947 33466.132 2409.84375 24679.71 
4         2 16858.531 11091.918 6134.682065 5430.857 
5         1 3409.1576 3574.7754 1624.274123 1947.342 
6         1 5939.7083 6706.6474 3280.776786 3921.551 
7         1 5575.7091 5968.7614 1861.035197 3679.04 
8         1 5430.5 7305.8146 4438.875 7470.86 
9         1 4088.4931 2711.7484 2159.346316 2250.374 
10         1 4972.649 4650.8059 7309.113636 6671.304 
11         1 3640.8278 3635.2159 2226.539474 2873.059 
12         1 3202.6667 3553.8215 1571.05848 3360.693 
13         1 7539.0632 6074.5132 11017.04545 6855.068 
14         1 3012.4915 6065.4511 2912.596491 5986.727 
15         1 61666.027 59799.133 48831.3 59207.47 
16         2 3946.6053 5780.2829 2564.313158 6329.356 
17         1 7169.1592 6736.6201 2745.842424 4774.744 
18         2 6443.0313 6736.6201 2932.332609 4774.744 
19         2 7169.1592 6443.0313 2745.842424 2932.333 
20         1 4839.7763 4774.05 7711.801136 5692.177 
21         2 30230.077 6068.0271 14745.76645 6985.551 
22         1 3683.1842 3874.9026 5567.27381 4508.612 
23         2 5484.9737 3997.9956 4153.742424 3374.373 
24         2 4064.2727 4119.9437 1722.509058 2864.858 
 
 
 
 
 
 
 
143 
 
 
ELISA Data 
 
Subject Group 
IL8 
POST1 
IL8 
POST2 
IL10 
POST1 
IL10 
POST2 
1         2 32011.643 17923.615 17837.3095 15091.7424 
2         2 14005.524 18176.232 7327.08571 7181.71053 
3         2 19125.286 35693.79 6825.79365 35333.2235 
4         2 37487.565 32427.758 10912.2336 12526.1571 
5         1 22323.303 19797.926 6239.225 6793.88651 
6         1 14679.452 17118.471 57529.2141 57915.6153 
7         1 14749.063 11123.893 6333.27083 8802.81548 
8         1 17095.109 18446.433 43515.5 50507.3023 
9         1 14493.977 11443.781 4558.88636 4460.59596 
10         1 10435.906 7843.9524 9748.08807 10497.2905 
11         1 19428.768 30138.751 9455.43333 9310.90625 
12         1 10196.625 16312.291 4655.0625 6360.18651 
13         1 19288.053 13443.397 12455.3153 16360.5089 
14         1 13450.385 22281.235 6488.73684 11566.5969 
15         1 57283.693 58939.545 63914.1417 64286.5222 
16         2 22513.852 34914.669 13901.7242 25501.5333 
17         1 15076.45 28707.681 7980.77964 19279.2352 
18         2 30405.347 28707.681 8933.50417 19279.2352 
19         2 15076.45 30405.347 7980.77964 8933.50417 
20         1 11902.431 11480.708 7844.89638 6568.83239 
21         2 38674.878 14938.835 9245.99048 12001.2083 
22         1 10155.357 11558.366 7715.206 6333.20707 
23         2 18970.098 14057.958 11162.3125 9244.99048 
24         2 21618.219 21622.093 5940.64145 8153.375 
 
 
 
144 
 
ELISA Data 
 
Subject Group 
IFNγ  
POST1 
IFNγ  
POST2 
TNFα  
POST1 
TNFα 
POST2 
1         2 11544.48864 10534.60885 14109.50595 12055.80159 
2         2 6778.71875 7087.766304 6297.410714 8410.766667 
3         2 5111.080702 22238.4366 6234.780952 35409.71198 
4         2 16896.17763 12028.58333 21794.97222 15942.27083 
5         1 3517.969697 3456.75744 6601.422807 5579.527778 
6         1 5796.9 6608.738636 18363.90625 20416.89123 
7         1 3754.548718 3546.760766 5541.292614 5596.59375 
8         1 5142.312121 6150.327122 12040.125 14475.32589 
9         1 4192.033333 3334.09375 4477.235119 4029.695489 
10         1 6744.906015 6893.1875 6713.405844 6471.809211 
11         1 4602.212121 4462.532164 7632.67619 7636.78125 
12         1 3585.058081 4188.737374 5021.029762 6139.152778 
13         1 13001.17506 10709.88587 15591.09673 11353.7803 
14         1 4745.430556 8749.056818 7135.428571 13480.95417 
15         1 40116.47727 51111.6622 63557.29602 63187.59447 
16         2 5244.702381 6632.202381 8291.674242 15172.5 
17         1 6929.90625 7074.139394 9079.698864 9716.526316 
18         2 5837.007576 7074.139394 9198.680556 9716.526316 
19         2 6929.90625 5837.007576 9079.698864 9198.680556 
20         1 5052.052676 5061.15625 7000.496528 5903.796491 
21         2 20697.84596 9022.136364 22603.70982 8352.9375 
22         1 4262.108333 4073.277778 5735.791228 5556.540179 
23         2 7244.016667 5257.956522 7623.1875 5988.129934 
24         2 4299.277273 4744.555556 8058.633333 7765.153533 
 
145 
 
ELISA DATA 
Standard Curve Densitometry Values 
IL-1α-Plate 
1 
 
IL-1β-Plate 1 
IL-2-Plate 
1 
 63408.21622 1 to 16 64454.027 1 to 16 64091.875 1 to 16 
63627.4375 1 to 32 64567.1081 1 to 32 64093.5185 1 to 32 
62059.84 1 to 64 63578.1515 1 to 64 63136.4545 1 to 64 
58641.95238 1 to 128 61357.5333 1 to 128 54543.7778 1 to 128 
12814.0625 Blank 4437.16667 Blank 12792.1333 Blank 
IL-1α-Plate 
2 
 
IL-1β-Plate 2 
IL-2-Plate 
2 
 62984.57895 1 to 16 63732.4667 1 to 16 63950 1 to 16 
63486.26667 1 to 32 64600.2973 1 to 32 63773.4 1 to 32 
60717.95652 1 to 64 62911.5625 1 to 64 57712.4762 1 to 64 
62351.8125 1 to 128 62511.7097 1 to 128 54050.4 1 to 128 
12003.7619 Blank 3779.23077 Blank 11036.7619 Blank 
IL-1α-Plate 
3 
 
IL-1β-Plate 3 
IL-2-Plate 
3 
 64375.7619 1 to 9 65535 1 to 9 63675.9737 1 to 9 
63492.28125 1 to 27 63585.973 1 to 27 63477.1071 1 to 27 
37837.36364 1 to 81 59213.5185 1 to 81 37801.9333 1 to 81 
20089.16667 1 to 243 29027.619 1 to 243 21222.4667 1 to 243 
11773.95455 1 to 729 12259.4737 1 to 729 6679.88889 1 to 729 
 
146 
 
ELISA DATA 
Standard Curve Densitometry Values 
IL-4-Plate 1 
 
IL-6-Plate 1 
 
IL-8-Plate 1 
 62106.58824 1 to 16 62778.28571 1 to 16 63677.8 1 to 16 
62595.48485 1 to 32 57426.5 1 to 32 63663.94118 1 to 32 
62575.65385 1 to 64 47105 1 to 64 64067.5 1 to 64 
56414.45455 1 to 128 20656.57895 1 to 128 59848.125 1 to 128 
12032.83333 Blank 4242.259259 Blank 7669.157895 Blank 
IL-4-Plate 2 
 
IL-6-Plate 2 
 
IL-8-Plate 2 
 62958.33333 1 to 16 63501.40625 1 to 16 63409.95455 1 to 16 
62212.51429 1 to 32 57899.38462 1 to 32 64820.38235 1 to 32 
60080.20833 1 to 64 32156.78261 1 to 64 62001.59259 1 to 64 
50245 1 to 128 27123.40909 1 to 128 59503.66667 1 to 128 
11460.2 Blank 3485.5 Blank 6948.277778 Blank 
IL-4-Plate 3 
 
IL-6-Plate 3 
 
IL-8-Plate 3 
 64134.2093 1 to 9 63829.82143 1 to 9 63781.55556 1 to 9 
63298.10526 1 to 27 51210.26923 1 to 27 62454.44737 1 to 27 
31768.96154 1 to 81 22068.17391 1 to 81 46509.95455 1 to 81 
15977.72222 1 to 243 10106.63636 1 to 243 20597.5 1 to 243 
13380.57895 1 to 729 5409.111111 1 to 729 12183.52381 1 to 729 
 
147 
 
ELISA DATA 
Standard Curve Densitometry Values 
IL-10-Plate 1 
 
TNF-α-Plate 1 
 
IFN-γ-Plate 1 
 15784.3913 1 to 16 60885.71429 1 to 16 64048.5 1 to 16 
13308.57143 1 to 32 61538.56522 1 to 32 62663.23333 1 to 32 
10232.68182 1 to 64 56314.69231 1 to 64 58122.57692 1 to 64 
7849.681818 1 to 128 39742.81818 1 to 128 51201.5625 1 to 128 
5444.636364 Blank 6620.695652 Blank 6336.26087 Blank 
IL-10-Plate 2 
 
TNF-α-Plate 2 
 
IFN-γ-Plate 2 
 38908.56522 1 to 16 64287.9375 1 to 16 63284.97059 1 to 16 
22095.5 1 to 32 62547.69231 1 to 32 61719.60714 1 to 32 
11670.61111 1 to 64 58187.9375 1 to 64 58269.5 1 to 64 
9557.625 1 to 128 47865.125 1 to 128 44207.125 1 to 128 
5171.368421 Blank 6242.16 Blank 6301.25 Blank 
IL-10-Plate 3 
 
TNF-α-Plate 3 
 
IFN-γ-Plate 3 
 61324.36364 1 to 9 63100.02439 1 to 9 64946.06818 1 to 9 
17518.38095 1 to 27 56836.38462 1 to 27 62766.29032 1 to 27 
6468.733333 1 to 81 27588.14286 1 to 81 30360.58333 1 to 81 
4945.130435 1 to 243 14535.05556 1 to 243 12834.55556 1 to 243 
4734.933333 1 to 729 8764.5 1 to 729 7836.772727 1 to 729 
 
 
